CMHC Boston Conference guide 2018 by JOSE WONG AD

ANNOUNCING . . .

Gilead Sciences Research Scholars Programs Each program provides financial support to two junior faculty researchers for a 2-year period, with each award funded up to $130,000 Awards are subject to separate terms and conditions

SCIENTIFIC REVIEW COMMITTEE Joseph A. Hill, MD, PhD Committee Chair UT Southwestern Medical Center Dallas, TX Joan Bathon, MD Columbia University New York, NY Robert E. Gerszten, MD Harvard Medical School Boston, MA Priscilla Hsue, MD University of California, San Francisco San Francisco, CA Robert Mentz, MD Duke University Durham, NC Ioana Preston, MD Tufts University Boston, MA

The mission of the Gilead Sciences Research Scholars Program in Cardiovascular Comorbidities is to support innovative scientific research that will advance knowledge in the field of cardiovascular comorbidities developed as a result of, or exacerbated by, metabolic disorders (e.g. nonalcoholic steatohepatitis), viral infection (e.g. HIV, HCV, HBV), , rheumatic autoimmune diseases (e.g., RA, SLE), or inflammatory bowel disease

For more information on the program, please visit the website: http://researchscholars.gilead.com

MAY 3-5, 2019 Phoenix, AZ Advancing Cardiometabolic Health from East to West Taking place at a venue that provides attendees a unique opportunity to learn about the Native American culture, the resort is built and designed to be a visually & structurally authentic representation of the Gila River Indian Community's heritage and culture--and celebrates the architecture, design, and legends of the Pima (Akimel O'otham) and Maricopa (Pee Posh) tribes.

Sheraton Grand at Wild Horse Pass: Arizona’s premier Native-American owned luxury resort

Not only is the venue devoted to cultural sustainability, with tribal heritage woven into each aspect of the resort, but the conference agenda will also focus on aspects of cardiometabolic health specific to indigenous communities. Sessions will spotlight: • Recent Results from Clinical Trials • Thought-Provoking & Innovative Educational Formats • Obesity and Lifestyle Medicine Research • Dyslipidemia, Atherosclerosis, and Thrombosis • Heart Failure and Hypertension • Diabetes Management Strategies

KEYNOTE SPERO M. MANSON, PHD: Highly distinguished public health professor "Health & Diabetes in the Native American Population" This lecture is designed to connect attendees with the geographical area's culture & proximate healthcare communities

ONSITE SPECIAL

www.cardiometabolichealth.org

WELCOME

Letter

The Cardiometabolic Event of the Year™

Welcome to the 13th Annual Cardiometabolic Health Congress! It is an exciting and stimulating time to be involved in the field of cardiometabolic health, as we continuously experience newly developed and introduced therapies, novel treatments, and inventive approaches: all of which collectively provide enhanced care and better patient outcomes. CMHC continues to confront and tackle the enormous clinical and economic challenges that cardiometabolic disease presents, providing dynamic and interactive educational opportunities surrounding the latest clinical research in the landscape of cardiometabolic care. CMHC is committed to spearheading, developing, and hosting the most clinically relevant conferences in cardiometabolic health—and bringing together a community of clinicians: all of whom have a vested interest in remaining at the intersection of science and medicine. This year’s meeting has been carefully curated to provide our attendees with the optimal educational experience, as we continue to improve both our educational methods & strategies, and ability to address the prevention, diagnosis, and management of cardiometabolic disease. The highly-anticipated pre-conference Women’s Health Summit: Cardiometabolic Health Across the Lifespan will commence on Wednesday, featuring noteworthy topics including cardio-oncology, cardiometabolic risk in PCOS, and hormone replacement therapy. Thursday will feature the popular session FDA Update and Late Breaking Clinical Trials, in addition to a lecture delivered by venerable keynote presenter C. Ronald Kahn, MD. The fully-packed agenda continues with stimulating sessions on both Friday and Saturday, including Day-to-Day Management of Obesity in Clinical Practice, Targeting Inflammation: Updates on Pathophysiology and Clinical Outcomes, and Overview of the New 2017 Hypertension Clinical Practice Guidelines. In addition to the extensive agenda, the conference will provide supplemental educational opportunities, with certified satellite symposia and professional medical education sessions. These highly-anticipated workshops have collectively been developed through the latest educational innovations, designed to enhance your learning experience through the utilization of infographics, iPads, animated videos, and simulations. Another newly introduced initiative, our Small Group Workshops, aims to provide you with a more intimate learning atmosphere, and enhanced educational experience. The four workshops will focus on attendee-requested topics such as sleep, digital health, and biosimilars, and are hosted in collaboration with the American Medical Association and the American Academy of Sleep Medicine. Not only is our agenda engineered to deliver the most current innovations and breakthroughs in science, but we have also expanded our Exhibit Hall—and increased our socializing & networking opportunities throughout the conference. Both the Poster Presentations and Passport to Prizes are back by popular demand, and our new Lifestyle Showcase features an area dedicated to companies that promote healthy lifestyle choices for cardiometabolic patients. CMHC attendees are encouraged to visit the Lifestyle Showcase and learn how to better incorporate healthy lifestyle options into their patients’ routines, to combat chronic diseases and enhance quality of life. On behalf of the entire CMHC team, we want to thank each of you for bringing your vision, expertise, and commitment to our event. As the leaders of the cardiometabolic field, you have the knowledge, motivation, and experience to help us pave the future of health—and are truly our greatest asset.

We hope you enjoy your stay in Boston and appreciate your continued dedication and support.

TABLE OF

Contents

CHAIRPERSONS CHRISTIE M. BALLANTYNE, MD Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

GEORGE L. BAKRIS, MD Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

ROBERT H. ECKEL, MD Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, T32 in Obesity and Cardiovascular Disease University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Aurora, CO

JAY S. SKYLER, MD Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

Welcome Letter

4-5

Hours of Operation

6-7

Meet the Experts

Book Signings

Schedule-at-a-Glance

9 - 11

Expert Speaker Line-Up

12 - 14

Exhibitor Index

Exhibitor Listings

19 - 25

Professional Medical Education (Non-CME)

26 - 27

Association & Media Partners

13th Annual CMHC Accreditation

Satellite CME Symposia

32 - 51

Scientific Poster Sessions

54 - 55

www.CardiometabolicHealth.org

n o i t a r e Op

HOURS OF REGISTRATION HOURS: WEDNESDAY OCTOBER 24

10:00 AM - 6:00 PM

THURSDAY OCTOBER 25

6:00 AM - 6:00 PM

FRIDAY OCTOBER 26

6:00 AM - 7:00 PM

SATURDAY OCTOBER 27 6:00 AM

6:00 AM - 1:00 PM 7:00 AM

8:00 AM

9:00 AM

10:00 AM

11:00 AM

12:00 PM

1:00 PM

2:00 PM

3:00 PM

4:00 PM

EXHIBIT HOURS:

5:00 PM

6:00 PM

7:00 PM

WELCOME RECEPTION

THURSDAY OCTOBER 25

10:15 AM11:15 AM

2:20 PM 3:20 PM

FRIDAY OCTOBER 26

10:00 AM 11:00 AM

2:20 PM 3:20 PM

5:10 PM 6:10 PM 6:05 PM 7:05 PM CLOSING RECEPTION

6:00 AM

7:00 AM

www.CardiometabolicHealth.org

8:00 AM

9:00 AM

10:00 AM

11:00 AM

12:00 PM

1:00 PM

2:00 PM

3:00 PM

4:00 PM

5:00 PM

6:00 PM

7:00 PM

MEET THE EXPERTS Located in the Exhibit Hall

SCIENTIFIC

THURSDAY OCTOBER 25 Morning Break 10:15 AM – 11:15 AM • Robert H. Eckel, MD • Jay S. Skyler, MD • Keith C. Ferdinand, MD • Christie M. Ballantyne, MD Afternoon Break 2:20 PM – 3:20 PM • Anne L. Peters, MD • Irl B. Hirsch, MD • Jay S. Skyler, MD

FRIDAY OCTOBER 26 Morning Break 10:00 AM - 11:00 AM • Robert H. Eckel, MD • Stephen Devries, MD • James O. Hill, PhD • Keith C. Ferdinand, MD • Cat Davis Ahmed, MBA • Deirdre J. Mattina, MD Afternoon Break 2:20 PM - 3:20 PM • Pamela B. Morris, MD • Pam R. Taub, MD • Gurusher S. Panjrath, MD • Akshay S. Desai, MD, MPH • Eldrin F. Lewis, MD, MPH

EXHIBIT HALL

BOOK SIGNINGS

For more information see pages 54-55

Located in the Exhibit Hall at the Elsevier Booth #413

FRIDAY OCTOBER 26

Morning Break 10:00 AM - 11:00 AM Christie M. Ballantyne, MD Afternoon Break 2:20 PM - 3:20 PM Peter Libby, MD

www.CardiometabolicHealth.org

at a Glance

e l u d e Sch

WEDNESDAY October 24 PRE-CONFERENCE “Women’s Health Summit: Cardiometabolic Health Across the Lifespan” 11:00 AM - 11:10 AM Introduction to CMHC Women’s Health Summit Chair: Pamela B. Morris, MD

11:10 AM - 11:55 AM Cardio-oncology: Overview and the Intersection Between Breast Cancer and Cardiovascular Disease Ana Barac, MD 12:00 PM - 1:00 PM

PME Lunch Symposium (Non-CME) Repatha® (evolocumab): Putting it into Practice Yehuda Handelsman, MD, FACP, FNLA, MACE Sponsored by Amgen, Inc.

1:10 PM - 1:15 PM

Welcome Back to Women’s Health Summit Chair: Pamela B. Morris, MD

1:15 PM - 1:45 PM Cardiometabolic Risk in PCOS and Implications for Management Andrea Dunaif, MD

I mpact of Pregnancy on CV Risk Factors and ASCVD Risk Pam R. Taub, MD

2:15 PM - 2:30 PM

Nutrition Break

1:45 PM - 2:15 PM

2:30 PM - 3:00 PM Choosing Wisely: Contraception in Women with Cardiometabolic Risk Nieca Goldberg, MD 3:00 PM - 3:30 PM Updates on the Role of Postmenopausal Hormone Replacement Therapy JoAnn E. Manson, MD Republic Ballroom

3:30 PM - 3:50 PM Women’s Health Summit Expert Panel Discussion and Q&A Chair: Pamela B. Morris, MD Panelists: Ana Barac, MD; Andrea Dunaif, MD; Nieca Goldberg, MD; Pam R. Taub, MD; JoAnn E. Manson, MD 3:50 PM - 4:00 PM Conclusions to CMHC Women’s Health Summit Chair: Pamela B. Morris, MD 4:00 PM - 4:15 PM

Mini Break

4:15 PM - 5:15 PM PME Light Bites (Non-CME) Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App & More Seth J. Baum, MD, FASPC; Howard S. Weintraub, MD, FASPC Sponsored by Amgen, Inc. and Sanofi Regeneron. 5:30 PM - 6:30 PM PME Light Bites (Non-CME) Long-Term Results of Treatment Across a Broad Range of Patients With Type 2 Diabetes Serge Jabbour, MD Sponsored by Janssen Pharmaceuticals, Inc. 6:45 PM - 7:45 PM PME Dinner Symposium (Non-CME) Cardiovascular Disease Burden in the US and Clinical Evaluation of VASCEPA® (icosapent ethyl) Robert S. Busch, MD, FACE Sponsored by Amarin Pharma, Inc.

Republic Foyer

www.CardiometabolicHealth.org

Schedule at a Glance

THURSDAY October 25 Session I: Diabetes Management 6:30 AM - 7:45 AM CME Breakfast Symposium A The Role of CGM in Individualization of T2DM Management Chair: Anne L. Peters, MD Presenter: Irl B. Hirsch, MD Supported by educational grants from Dexcom, Inc. and Medtronic. 6:30 AM - 7:45 AM CME Breakfast Symposium B Non-Medical Switching Barriers and Consequences Chair: Seth J. Baum, MD, FASPC Presenters: Kim Newlin, NP, CNS, FPCNA, FAHA Supported by educational grants from BMS Pfizer Alliance and Janssen Pharmaceuticals, Inc. 7:55 AM - 8:00 AM Opening Remarks Jay S. Skyler, MD

8:00 AM - 9:30 AM FDA Update and Late Breaking Trials Chair: Christie M. Ballantyne, MD Presenters: Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Jay S. Skyler, MD 9:30 AM - 10:15 AM Keynote C. Ronald Kahn, MD 10:15 AM - 11:15 AM Morning Break and Exhibits 10:20 AM - 11:15 AM

12:10 PM - 1:25 PM CME Lunch Symposium A Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression Chair: Matthew R. Weir, MD Presenters: Robert D. Toto, MD; Lance Sloan, MD Supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. and by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. www.CardiometabolicHealth.org

FRIDAY October 26

1:35 PM - 2:20 PM Where Are We With Devices for Diabetes Management? Anne L. Peters, MD

6:30 AM - 7:45 AM CME Breakfast Symposium A The ABC Access Program: Overcoming Barriers to Access of Newer Cardiovascular Agents for High-Risk and Minority Patients Chair: Keith C. Ferdinand, MD Presenters: Deirdre J. Mattina, MD; Catherine Davis Ahmed, MBA This activity is supported by an educational funding donation provided by Amgen and in partnership with the Association of Black Cardiologists, Inc (ABC).

2:20 PM - 3:20 PM Afternoon Break and Exhibits 3:20 PM - 3:50 PM How Many GLP-1 RAs Do We Need and Why? John B. Buse, MD 3:50 PM - 5:05 PM Multidisciplinary Case Consults in Diabetes Management Chair: Jay S. Skyler, MD Panelists: John B. Buse, MD; Robert H. Eckel, MD; Davida Kruger, MSN, APN-BC, BC-ADM; Anne L. Peters, MD; Irl B. Hirsch, MD 4:00 PM - 4:45 PM Small Group Workshop Real-world Digital Health Implementations to Improve Blood Pressure Control Kate Kirley, MD, MS Janet Williams, MA Hosted in Collaboration with the American Medical Association. Registration Required 5:10 PM - 6:10 PM Welcome Reception Best Scientific Poster will be announced

Small Group Workshop Insulin Biosimilars Anne L. Peters, MD Registration Required

11:15 AM - 12:00 PM So Many Options - Dispelling the Confusion About Insulins Irl B. Hirsch, MD This session is supported by an educational grant from Novo Nordisk.

12:10 PM - 1:25 PM CME Lunch Symposium B Advances in HFpEF: Addressing Diagnostic and Treatment Challenges Chair: JoAnn Lindenfeld, MD Presenters: Keith C. Ferdinand, MD; Alanna A. Morris, MD Supported by an educational grant from Novartis Pharmaceuticals Corporation.

6:15 PM - 7:30 PM CME Dinner Symposium Mastering the Prior Authorization Process to Meet Patient Needs Chair: Pamela B. Morris, MD Presenters: Christie M. Ballantyne, MD; Kim K. Birtcher, PharmD; Matthew Stryker, PharmD, BCACP, CLS Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals and in partnership with The DoctorPatient Rights Project.

Constitution Ballroom

Grand Ballroom

Session II: Obesity and Lifestyle Management in Cardiovascular Disease

6:30 AM - 7:45 AM CME Breakfast Symposium B Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice Chair: Robert H. Eckel, MD Presenters: Deepak L. Bhatt, MD, MPH; Harold E. Bays, MD; Lawrence Blonde, MD Supported by educational grants from AstraZeneca and Novo Nordisk. 7:55 AM - 8:00 AM Opening Remarks Robert H. Eckel, MD 8:00 AM - 8:45 AM Interventional Cardiology Delivered With a Fork Stephen Devries, MD

Pre-registration is not required for satellite symposia or PMEs Exhibit Hall

Grand Foyer

9:15 AM - 10:00 AM Obesity and Environmental Influence: The Big Picture James O. Hill, PhD 10:00 AM - 11:00 AM Morning Break and Exhibits 10:05 AM - 10:50 AM Small Group Workshop Prevent Type 2 Diabetes with Digital Health: Effective and Realistic Solutions Kate Kirley, MD, MS Janet Williams, MA Hosted in Collaboration with the American Medical Association. Registration Required 11:00 AM - 11:45 AM Day to Day Management of Obesity in Clinical Practice Robert F. Kushner, MD 11:45 AM - 11:50 AM Closing Remarks Robert H. Eckel, MD 12:00 PM - 1:15 PM CME Lunch Symposium A Identifying, Diagnosing and Managing Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life Chair: Eldrin F. Lewis, MD, MPH Presenters: Akshay S. Desai, MD, MPH; Gurusher S. Panjrath MD, FACC, FAHA Supported by an educational grant from American Regent.

SATURDAY October 27 Session IV: Hypertension, Cardio-renal, and Heart Failure 6:30 AM - 7:45 AM CME Breakfast Symposium Finding the Balance: Treatment and Management of Hyperkalemia in Patients with Heart Failure and Chronic Kidney Disease Chair: George L. Bakris, MD Presenter: Keith C. Ferdinand, MD Supported by an educational grant from Relypsa, Inc. Constitution Ballroom

Grand Ballroom

12:00 PM - 1:15 PM CME Lunch Symposium B New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia Chair: Robert E. Ratner, MD Presenters: Robert H. Eckel, MD; Davida Kruger, MSN, APN-BC, BCADM; Deborah J. Wexler, MD Supported by an educational grant from Sanofi US.

Session III: Dyslipidemia, Atherosclerosis, and Cardiovascular Disease Risk Reduction 1:25 PM - 1:30 PM Opening Remarks Christie M. Ballantyne, MD 1:30 PM - 2:20 PM Targeting Inflammation: Updates on Pathophysiology and Clinical Outcomes Peter Libby, MD; Paul M. Ridker, MD This session is supported by an educational grant from Novartis Pharmaceuticals Corporation. 2:20 PM - 3:20 PM Afternoon Break and Exhibits 3:20 PM - 4:10 PM How Aggressively Do We Lower LDL-C and For Which Patients? Vera A. Bittner, MD; Marc S. Sabatine, MD 3:25 PM - 4:10 PM Small Group Workshop Don’t Hit the Snooze Button on Sleep: The Role of Sleep in Cardiometabolic Health Lawrence J. Epstein, MD Hosted in Collaboration with the American Academy of Sleep Medicine. Registration Required

7:55 AM - 8:00 AM Opening Remarks George L. Bakris, MD 8:00 AM - 9:00 AM Overview of the New 2017 Hypertension Clinical Practice Guidelines George L. Bakris, MD 9:00 AM - 9:30 AM Comparing the Hypertension Guidelines - Where is the Equipoise? Michael A. Weber, MD 9:30 AM - 9:45 AM Nutrition Break 9:45 AM - 10:45 AM Patient Cases: How would you change the management of hypertension based on the new guidelines? Aldo Peixoto, MD; Michael A. Weber, MD; Keith C. Ferdinand, MD Exhibit Hall

Grand Foyer

4:10 PM - 5:00 PM Risk Assessment for Global Cardiovascular Disease: Imaging and Biomarkers Matthew J. Budoff, MD; James De Lemos, MD

Schedule at a Glance

8:45 AM - 9:15 AM Updates on Metabolic Surgery Mary-Elizabeth Patti, MD

5:00 PM - 6:00 PM Multidisciplinary Case Consults in Lipid Disorders Chair: Christie M. Ballantyne, MD Panelists: Vera A. Bittner, MD; Robert H. Eckel, MD; Pamela B. Morris, MD; Margo B. Minissian, PhD, ACNP; Pam R. Taub, MD This session is supported by educational grants from Amarin Pharma, Inc and Akcea Therapeutics. 6:00 PM - 6:05 PM Closing Remarks Christie M. Ballantyne, MD

6:05 PM - 7:05 PM Closing Reception Passport to Prizes winners will be announced 7:15 PM - 8:15 PM PME Dinner Symposium (Non-CME) Advancements in the Management of Patients with Type 2 Diabetes: Results from a Large Cardiovascular Outcomes Trial Ronald D’Agostino, DO, FACC, FACP Sponsored by Novo Nordisk.

10:45 AM - 11:15 AM Prevention of Heart Failure: The Next Frontier Peter A. McCollough, MD 11:15 AM - 11:25 AM Mini Break 11:25 AM - 11:55 AM Integration of Biomarkers and Prediction of AKI and Cardio-renal Outcomes in Clinical Practice Aldo Peixoto, MD 11:55 AM - 12:25 PM AKI and Heart Failure: How to manage compared to general population? Peter A. McCollough, MD 12:25 PM - 12:55 PM Advanced CKD and Benefits from CVOTs Jorge Plutzky, MD 12:55 PM - 1:00 PM Closing Remarks George L. Bakris, MD www.CardiometabolicHealth.org

EXPERT p SPEAKER U e n i L Chairpersons Christie M. Ballantyne, MD

George L. Bakris, MD

Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

Senior Planning Committee

Vice President, Policy and Outreach The FH Foundation Pasadena, CA

Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Deepak L. Bhatt, MD, MPH Professor of Medicine Harvard Medical School Executive Director Interventional Cardiovascular Programs Brigham and Women’s Hospital Heart and Vascular Center Boston, MA

Catherine Davis Ahmed, MBA

Ana Barac, MD, PhD, FACC Associate Professor of Medicine Director, Cardio-oncology Program Medstar Heart and Vascular Institute Georgetown University Washington, DC

www.CardiometabolicHealth.org

Robert H. Eckel, MD

Jay S. Skyler, MD

Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, T32 in Obesity and Cardiovascular Disease University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Aurora, CO

Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

Seth J. Baum, FASPC, MD** Immediate Past-President, American Society for Preventive Cardiology Excel Medical Clinical Trials, LLC Founder, Chief Medical Officer Clinical Affiliate Professor of Biomedical Science Department of Integrated Medical Sciences Florida Atlantic University Charles E. Schmidt College of Medicine Medical Director, Women’s Preventive Cardiology Christine E. Lynn Women’s Health & Wellness Institute Boca Raton Regional Hospital Boca Raton, FL

*Professional Medical Education (PME) presenter

Pamela B. Morris, MD Director, Seinsheimer Cardiovascular Health Program Co-Director, Women’s Heart Care Medical University of South Carolina Charleston, SC

Harold E. Bays, MD

Medical Director/President Louisville Metabolic and Atherosclerosis Research Center, Inc. Louisville, KY

Professor of Medicine, Pediatrics, & Psychology Division of Endocrinology, Diabetes & Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical & Academic Programs Diabetes Research Institute Miami, FL

Clyde W. Yancy, MD, MSc, MACP Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Div. of Cardiology, Northwestern Univ. Feinberg School of Medicine Assoc. Director, Bluhm Cardiovascular Institute Northwestern Memorial Hospital Chicago, IL

Kim K. Birtcher, PharmD Clinical Professor University of Houston College of Pharmacy Houston, TX

**PME presenter and General Session/CME Symposium presenter

Vera Bittner, MD, MSPH Professor of Medicine Section Head, General Cardiology, Prevention and Imaging Division of Cardiovascular Disease University of Alabama at Birmingham Birmingham, AL

Ronald D’Agostino, DO, FACC, FACP* New York University School of Medicine New York, NY

Lawrence J. Epstein, MD Instructor in Medicine, Harvard Medical School Assistant Medical Director, Brigham Sleep Medicine Brigham and Women’s Hospital Boston, MA

Serge Jabbour, MD* Professor of Medicine Director, Division of Endocrinology, Diabetes & Metabolic Diseases Sidney Kimmel Medical College of Thomas Jefferson University Philadelphia, PA

Eldrin F. Lewis, MD, MPH Director Cardiovascular Clerkships and STARS Research Program, Brigham and Women’s Hospital BWH Clinical Endpoints Center Associate Professor of Medicine, Harvard Medical School Boston, MA

Lawrence Blonde, MD

Director, Ochsner Diabetes Clinical Research Unit Frank Riddick Diabetes Institute Department of Endocrinology Ochsner Medical Center New Orleans, LA

James de Lemos, MD

Professor of Medicine University of Texas Southwestern Medical Center Dallas, TX

Nieca Goldberg, MD

Medical Director, Joan H. Tisch Center for Women’s Health NYU Langone Medical Center Clinical Associate Professor of Medicine NYU School of Medicine New York, NY

C. Ronald Kahn, MD

Mary K. Iacocca Professor of Medicine Harvard Medical School Chief Academic Officer Joslin Diabetes Center Boston, MA

Peter Libby, MD

Mallinckrodt Professor of Medicine Harvard Medical School Cardiovascular Specialist Brigham and Women’s Hospital Boston, MA

Matthew J. Budoff, MD

Professor of Medicine David Geffen School of Medicine Program Director & Director of Cardiac CT Division of Cardiology Harbor-UCLA Medical Center Torrance, CA

Akshay S. Desai, MD, MPH Associate Professor of Medicine, Harvard Medical School Director, Cardiomyopathy and Heart Failure Advanced Heart Disease Section Cardiovascular Division Brigham and Women’s Hospital Boston, MA

Yehuda Handelsman, MD* Medical Director and Principal Investigator Metabolic Institute of America Tarzana, CA

Kate Kirley, MD, MS Director of Chronic Disease Prevention American Medical Association Chicago, IL

JoAnn Lindenfeld, MD Director, Heart Failure and Transplant Professor of Medicine Vanderbilt University School of Medicine Nashville, TN

Robert Busch, MD* Director of Clinical Research Albany Medical College Faculty Practice: Community Endocrine Group Albany, NY

Stephen Devries, MD, FACC Executive Director Gaples Institute for Integrative Cardiology Deerfield, IL

John B. Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Director, Diabetes Center Director, NC Translational and Clinical Sciences Institute Executive Associate Dean, Clinical Research University of North Carolina School of Medicine Chapel Hill, NC

Andrea Dunaif, MD Lillian and Henry M. Stratton Professor of Molecular Medicine Chief of the J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai New York, NY

James O. Hill, PhD

Irl B. Hirsch, MD

Professor University of Colorado School of Medicine Denver, CO

Professor of Medicine Diabetes Treatment and Teaching Chair University of Washington Medical Center Medical Director UWMC Diabetes Care Center Seattle, WA

Davida F. Kruger, MSN, APNBC, BCADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease Detroit, MI

JoAnn E. Manson, MD, DrPH, FAHA Chief, Division of Preventive Medicine Brigham and Women’s Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women’s Health Harvard Medical School Professor, Department of Epidemiology Harvard T.H. Chan School of Public Health Boston, MA

Robert Kushner, MD Professor of Medicine Division of General Internal Medicine Northwestern University Feinberg School of Medicine Clinical Director Northwestern Comprehensive Center on Obesity Medical Director Center for Lifestyle Medicine Chicago, IL

Deirdre J. Mattina, MD Senior Staff Physician, Division of Cardiology Director, Women’s Heart Center Henry Ford Hospital Detroit, MI

www.CardiometabolicHealth.org

Peter A. McCullough, MD, MPH Professor of Medicine Vice Chief of Internal Medicine Baylor University Medical Center Dallas, TX

Margo Minissian, PhD, ACNP Nurse Scientist Cardiology Nurse Practitioner Clinical Lipid Specialist Barbra Streisand Women’s Heart Center, Cedars-Sinai Heart Institute Los Angeles, CA

Aldo J. Peixoto, MD

Mary-Elizabeth Patti, MD

Associate Professor of Medicine, Harvard Medical School Investigator/Adult Endocrinology Joslin Diabetes Center Boston, MA

Professor of Medicine (Nephrology) Yale School of Medicine Associate Chair for Ambulatory Operations and Quality Department of Internal Medicine Clinical Chief, Section of Nephrology Director, Yale Hypertension Center New Haven, CT

Marc S. Sabatine, MD, MPH

Paul M. Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Boston, MA

Chairman, TIMI Study Group Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA

Michael A. Weber, MD

Robert D. Toto, MD Professor of Medicine Associate Dean for Clinical and Translational Research University of Texas Southwestern Medical Center Dallas Dallas, TX

Professor of Medicine State University of New York Downstate College of Medicine Brooklyn, NY

Janet Williams, MA Senior Manager Physician and Health System Engagement, Improving Health Outcomes American Medical Association Chicago, IL

www.CardiometabolicHealth.org

Alanna A. Morris, MD

Assistant Professor of Medicine, Division of Cardiology Emory University Clinical Cardiovascular Research Institute Atlanta, GA

Anne L. Peters, MD

Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California Los Angeles, CA

Lance Sloan, MD, FACE, FASN Clinical Assistant Professor - UTMB Galveston, TX Medical Director of The Texas Institute for Kidney and Endocrine Disorders - Lufkin, TX Medical Director of HC Polk Education Center - Lufkin, TX Medical Director of SNG Dialysis - Lufkin, TX

Howard S. Weintraub, MD* Treasurer, American Society for Preventive Cardiology Clinical Professor Department of Medicine Clinical Director Center for Prevention of Cardiovascular Disease NYU Langone Medical Center New York, NY

Kim Newlin, NP, CNS, FPCNA, FAHA Advanced Practice Nurse Clinical Manager Sutter Health/Preventive Cardiovascular Nurses Association Sutter Roseville Medical Center Roseville, CA

Jorge Plutzky, MD

Director, The Vascular Disease Prevention Program Director, Preventive Cardiology Associate Professor, Harvard Medical School Brigham and Women’s Hospital, Division of Cardiovascular Medicine Boston, MA

Matthew D. Stryker, PharmD, BCACP, CLS Assistant Professor Albany College of Pharmacy and Health Sciences Albany Medical Center – Division of Community Endocrinology Albany, NY

Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Baltimore, MD

Gurusher S. Panjrath MD, FACC, FAHA Director, Heart Failure and Mechanical Circulatory Support Program Associate Professor of Medicine George Washington University School of Medicine Washington DC

Robert E. Ratner, MD Professor of Medicine Georgetown University School of Medicine Washington, DC

Pam Taub, MD, FACC Associate Professor of Medicine Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center UC San Diego Health System Division of Cardiovascular Medicine La Jolla, CA

Deborah J. Wexler, MD, MSc Associate Professor of Medicine, Harvard Medical School Associate Clinical Chief, MGH Diabetes Center Massachusetts General Hospital Boston, MA

EXPERT SPEAKER Line-Up

www.CardiometabolicHealth.org

EXHIBITOR INDEX EXHIBIT HOURS:

WELCOME RECEPTION

THURSDAY OCTOBER 25

10:15 AM11:15 AM

2:20 PM 3:20 PM

FRIDAY OCTOBER 26

10:00 AM 11:00 AM

2:20 PM 3:20 PM

5:10 PM 6:10 PM 6:05 PM 7:05 PM CLOSING RECEPTION

6:00 AM

7:00 AM

8:00 AM

9:00 AM

10:00 AM

11:00 AM

12:00 PM

1:00 PM

2:00 PM

3:00 PM

4:00 PM

5:00 PM

Company name

Amarin Pharma, Inc.

InBody

Amgen

L-Nutra, Inc

Arbor Pharmaceuticals

Merck & Co., Inc.

Berkeley Life Professional

Metagenics

Boehringer-Ingelheim

New England Medical Books

Cleveland Heart Lab

Novo Nordisk

CoachCare

Ortho Molecular Products

Corcept Therapeutics

Regeneron / Sanofi

Daiichi Sankyo Inc.

SpectraCell Laboratories

Gaples Institute

T.A. Sciences, Inc.

Genova Diagnostics

UNIsource Health Inc

6:00 PM

7:00 PM

Ideal Protein of America

www.CardiometabolicHealth.org

Walkiria Type 1 Diabetes

Because nothing should come between grandma and a hug. It takes more than medicines to feel better when you have a chronic condition. That’s why, for nearly a century, Novo Nordisk has been making medicines and developing partnerships to raise awareness, improve prevention, promote early diagnosis and expand access to care for people living with diabetes and other chronic diseases. For more information on all that we’re doing, visit novonordisk.us

EXHIBITOR LISTINGS

Amarin Pharma, Inc.

Arbor Pharmaceuticals

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www. vascepa.com. For more information visit www.amarincorp.com.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital, neuroscience, and pediatric markets. Visit www.arborpharma.com or send email inquiries to info@arborpharma.com

1430 Route 206, Suite 200 Bedminster, NJ 07921 908-719-1315 https://www.amarincorp.com/

Amgen

One Amgen Center Drive Thousand Oaks, CA 91320 8054474568 www.amgen.com Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

6 Concourse Parkway, Ste 1800 Atlanta, GA 30328 678-334-2420 www.arborpharma.com

Berkeley Life Professional 355 North Canal Street Chicago, IL 60606 7737507745 www.berkeleylifeprofessional.com

Berkeley Life Professional helps support Nitric Oxide (NO) levels for a healthy cardiovascular system by supplementing your diet with dietary nitrates. Berkeley Life Professional supplements provides the dietary nitrates found in plants to help support NO levels, cardiovascular health, and overall health and vitality. Our patented Berkeley Test Nitric Oxide Test Strips enable you to check your Nitric Oxide levels in seconds. They are an easy to use non-invasive saliva test. Berkeley Life’s combined solution helps support Nitric Oxide for a healthy cardiovascular system.

Boehringer-Ingelheim

900 Ridgebury Rd PO Box 368 Ridgefield, CT 06877 800-243-0127 www.boehringer-ingelheim.com Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

Cleveland Heart Lab

500 Plaza Drive Secaucus, NJ 07094 9735202700 www.clevelandheartlab.com “Cleveland HeartLab is a premier, nextgeneration clinical reference laboratory committed to advancing cardiovascular risk assessment through unique and novel biomarkers. CHL offers unique inflammation testing which provides additional and complementary insight into cardiovascular risk beyond cholesterol testing alone. This additional information allows for targeted treatment to reduce risk over one’s lifetime.”

www.CardiometabolicHealth.org

LEARN MORE ABOUT

EXHIBITOR LISTINGS

CoachCare

Daiichi Sankyo, Inc.

Genova Diagnostics

CoachCare helps health clinics improve retention, referrals and revenue by encouraging 24/ 7 patient-clinic engagement and simplifying daily complexities through a custom-branded patient mobile app, clinical dashboard, and connected devices. CoachCare drives industry-leading patient engagement for its clinic clients across many key metrics, including consultations, weigh-ins and activity levels.

Daiichi Sankyo, Inc. headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development, also located in Basking Ridge. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioidinduced constipation, IV iron therapy and metastatic melanoma.

Genova Diagnostics is a leading clinical laboratory applying systems-based testing approaches to the diagnosis, treatment and prevention of complex chronic disease. Genova specializes in clinical laboratory services with actionable information.

150 W 28th St, Ste. 502 New York, NY 10001 646-598-8327 www.CoachCare.com

Corcept Therapeutics 149 Commonwealth Drive Menlo Park, CA 94025 650-327-3270 www.corcept.com

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. KorlymÂŽ is the companyâ&#x20AC;&#x2122;s first FDA-approved medication. Korlym inhibits the effects of excess cortisol in patients with hypercortisolism by modulating activity at the glucocorticoid receptor, one of the two receptors to which cortisol binds.

211 Mt. Airy Rd. Basking Ridge, NJ 07920 908-992-6400 www.dsi.com

Gaples Institute

655 Deerfield Road Ste 100-328 Deerfield, IL, 60015 847-607-9740 integrate@gaplesinstitute.org The Gaples Institute is an educational nonprofit with the goal of advancing the role of nutrition and lifestyle in health care. The organization, led by preventive cardiologist, Dr. Stephen Devries, is supported by an advisory board that includes national leaders in medicine, education, and philanthropy. Gaples Institute educational projects include: a wide range of public education resources available on their website, a 3-hour continuing education, interactive course for health professionals on nutrition science and counseling, and conferences that combine nutrition science with handson cooking. Gaples Institute advocacy work includes initiatives to remedy the current deficiency of nutrition education requirements for physicians in training.

63 Zillicoa St Asheville, NC 28801 18005224762 www.gdx.net

Ideal Protein of America 3135 SR580, Suite 5 Safety Harbor, FL 34695 8663144447 www.idealprotein.com

The Ideal Protein Weight Loss Protocol is medically designed and developed and is consistent with evidence-based guidelines, to help obese and overweight patients or clients achieve safe, long-term weight loss and maintain it. The Protocol helps to reverse the imbalance in insulin that occurs with the typical Western diet and that contributes to weight gain and metabolic syndrome. Physicians report that after successful completion of the Ideal Protein Weight Loss Protocol, patients experience significant improvement in metabolic parameters. Individualized, professional health coaching helps patients or clients learn proper nutrition and new eating habits

www.CardiometabolicHealth.org

Going Beyond Traditional Risk Factors with a Personalized Approach to Cardiovascular Disease Spectracell’s CardioMetabolic analysis goes beyond standard cholesterol screening to help define risk for atherosclerotic cardiovascular disease (ASCVD), progression toward Type 2 Diabetes, and inflammation conditions that typically precede heart attacks, stroke, and diabetes. CardioMetabolic Profile:

• CardioMetabolic and Type 2 Diabetes risk assessments • Lipoprotein Particle Profile® Plus - measures lipoprotein size and density; cardiovascular risk stratification; and also includes triglyceride and traditional cholesterol screening • OmegaCheck® - measures the ration of omega-6 to omega-3 fatty acids in one’s blood

One step further... Micronutrients are involved in the body’s countless metabolic reactions; therefore, a single deficiency can affect cardiac and metabolic health. SpectraCell’s proprietary Micronutrient analysis is the only scientific and objective assessment of functional intracellular micronutrient status, measuring the functional levels of 31 vitamins, minerals, fatty acids, antioxidants, and metabolites. Your patient’s story is unique. Their wellness plan should be too.

10401 Town Park Drive | Houston, TX 77072 | 800.227.5227 | www.spectracell.com

EXHIBITOR LISTINGS

InBody

Merck & Co., Inc.

InBody is a global leader in body composition analysis. Our medical-grade bioelectrical impedance devices are used in leading medical clinics and research facilities worldwide. The InBody 770 tracks muscle mass, body water, water imbalances, and fat in each of the arms, trunk, and legs separately, making it an accurate and noninvasive method for evaluating sarcopenia and frailty.

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

13850 Cerritos Corporate Dr, Suite C Cerritos, CA 90703 3239326503 www.inbody.com

L-Nutra, Inc

8322 Beverly Blvd, Ste 202 Los Angeles, CA 90048 310.775.3655 www.prolonpro.com L-Nutra, Inc. is based in Los Angeles, California and was founded eight years ago with the mission to develop the Fasting Mimicking Diet (FMD) and make it available to improve consumers’ lives worldwide. L-Nutra’s team of researchers and collaborators are scientific leaders in the field of nutrition related to longevity and healthspan. They develop nutri-technologies that mimic and enhance the effects of fasting, unleashing the body’s natural ability to rejuvenate itself and promote longevity. The first fasting mimicking diet from L-Nutra is ProLon®, a plant-based 5-day meal replacement consumed just 5 consecutive days a month. ProLon has been clinically tested and found to promote beneficial effects in a wide variety of conditions ranging from excess weight and fasting blood glucose, to growth factors associated with DNA damage and aging. For more information, visit www.l-nutra.com.

2000 Galloping Hill Road Kenilworth, NJ 07033 1-800-444-2080 www.merck.com

Metagenics

25 Enterprise, Suite 200 Aliso Viejo, CA 92656 800-692-9400 www.metagenics.com Metagenics was founded on a revolutionary idea: Our genes do not predetermine our health potential, and through nutrition, we can impact how our genes express themselves. Embodied by our company motto—genetic potential through nutrition—this groundbreaking principle drives us to deliver high-quality, science-based nutritional supplements, medical foods, and lifestyle programs to support healthcare practitioners in their efforts to help patients achieve their health goals. With a range of nutritional solutions designed to support individual lifestyles, including non-GMO, gluten-free, and vegetarian offerings, we remain committed to supplying practitioners around the world with advanced tools to help improve patient outcomes.

New England Medical Books 22 Hedgefield Court Orange, CT 06477 203-915-6576

Medical Books and Electronic Product from Elsevier Medical Publishers including the New Edition of Braunwald’s Heart Disease 11th Edition and all of the companion publications.

Novo Nordisk

800 Scudders Mill Rd. Plainsboro, NJ 08536 609-786-4680 novonordisk-us.com For more than 90 years, Novo Nordisk, a global leader in diabetes care, has been changing diabetes. We make innovative medicines to help people with diabetes manage their disease, believe that people should have access to care and treatment options, and offer support programs for patients. Our ultimate goal is to defeat diabetes through prevention, detection and better management, and empower people with diabetes to live longer, healthier lives. We have built our business on the conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way.

www.CardiometabolicHealth.org

EXHIBITOR LISTINGS

Ortho Molecular Products

SpectraCell Laboratories

UNIsource Health Inc

For over 25 years, Ortho Molecular Products has partnered exclusively with health care providers to deliver nutritional solutions of the highest efficacy. The most trusted voices in health care put their trust in our products to help patients get better, faster. Our commitment to science, careful raw ingredient selection, and strict quality standards goes into every supplement we formulate. To learn more, visit www.orthomolecularproducts. com or call 1-800-332-2351.

SpectraCell Laboratories, Inc. is a leading clinical laboratory specializing in personalized disease prevention and management solutions. Our pioneering nutritional and cardiometabolic testing, driven by state-of-the-art technology, assesses a spectrum of risk factors and biomarkers for optimum wellness. Through our dedication to research and development, SpectraCell also provides innovative solutions for hormone health and genetics. We are committed to providing scientific excellence, superior disease prevention and management solutions, and the highest quality of service to clients and their patients worldwide.

UniSource Health offers the RM-3A Medical Device. It is a five time FDA cleared device which provides an innovative unique fast analytical screening system for risk factors pertaining to diabetes, cardiovascular disease, neuropathy and ANS dysfunction as well as other wellness and longevity markers. The non-invasive RM-3A and ABI devices are designed for in-practice early detection of risk variables offering up-to-the-minute data essential to whole-person analysis.

1991 Duncan Pl Woodstock, IL 60098 8152066500 www.orthomolecularproducts.com

Regeneron / Sanofi

777 Old Saw Mill River Road Tarrytown, NY 10591 855-734-3648 https://www.regeneron.com/ Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

10401 Town Park Drive Houston, TX 77072 8002275227 www.spectracell.com

1894 E Williams St, Suite 307 Carson City, NV 89701 775 883-6465 unisourcehealth.com

T.A. Sciences, Inc.

420 Lexington Avenue, Suite 2900 New York, NY 10170 212-588-8805 www.tasciences.com T.A. Sciences® is dedicated exclusively to creating research-based, clinically tested wellness products that help address cellular aging through the science of Telomerase Activation. Built upon a foundation strongly grounded in scientific evidence, T.A. Sciences® is widely recognized as the leader in the field of Telomere Biology. T.A. Sciences® spends millions each year on leading edge scientific research, including double-blind, placebo-controlled studies proving the safety and effectiveness of its premiere product, TA-65. Founded in 2002, T.A. Sciences® is headquartered in New York City. www.CardiometabolicHealth.org

PROFESSIONAL MEDICAL EDUCATION (NON - CME)

WEDNESDAY OCTOBER 24

PME Lunch Symposium (Non-CME)

12:00 PM - 1:00 PM | Republic Ballroom Repatha® (evolocumab): Putting it into Practice Yehuda Handelsman, MD, FACP, FNLA, MACE Join Dr. Handelsman for an educational presentation on the importance of Repatha® (evolocumab). Hear about his experience with Repatha, and the options available for appropriate patients. Sponsored by Amgen, Inc.

Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.

PME Light Bites (Non-CME)

4:15 PM - 5:15 PM | Republic Ballroom Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App & More Seth J. Baum, MD, FASPC; Howard S. Weintraub, MD, FASPC Learn how to access PCSK9 Inhibitors using the novel mobile app developed by the American Society for Preventive Cardiology (ASPC). This innovative tool includes a simple-10step approach, single page prior authorization and appeal letters published by the ASPC, the Association of Clinical Endocrinologists, valuation models of drugs, case studies, references to key papers, names of “best and worst” insurance companies in each state, links to advocacy sites, information on specialty pharmacies, and so much more. Sponsored by Amgen Inc. and Sanofi Regeneron

PME Light Bites (Non-CME)

5:30 PM - 6:30 PM | Republic Ballroom Long-Term Results of Treatment Across a Broad Range of Patients With Type 2 Diabetes Serge Jabbour, MD This program will cover long-term results of treatment with a sodium-glucose co-transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes. Topics include the pathophysiology of type 2 diabetes and its associated cardiometabolic risk factors; how SGLT2 inhibitors work; key efficacy and safety results, including results from longer-term follow-up, results from active-controlled studies supporting the use of SGLT2 inhibitors versus other agents, and results from a network meta-analysis of SGLT2 inhibitors; and important safety information, followed by a question-and-answer session. This promotional educational activity is sponsored by Janssen Pharmaceuticals, Inc.

FRIDAY

OCTOBER 26 PME Dinner Symposium (Non-CME)

7:15 PM - 8:15 PM | Constitution Ballroom Advancements in the Management of Patients with Type 2 Diabetes: Results from a Large Cardiovascular Outcomes Trial Ronald Dâ&#x20AC;&#x2122;Agostino, DO, FACC, FACP

Sponsored by Janssen Pharmaceuticals, Inc.

This program will review data from a large cardiovascular outcomes trial and its impact on the management of type 2 diabetes.

PME Dinner Symposium (Non-CME)

Sponsored by Novo Nordisk.

6:45 PM - 7:45 PM | Republic Ballroom Cardiovascular Disease Burden in the US and Clinical Evaluation of VASCEPA (icosapent ethyl) Robert S. Busch, MD, FACE Hear from an expert about cardiovascular disease burden in the United States and clinical evaluation of VASCEPA (icosapent ethyl). Despite the benefits of LDL-C lowering, many patients on statin therapy remain at risk. In this presentation, data and perspectives on the role of high triglycerides as a marker of increased cardiovascular risk in patients with statin-controlled LDL-C will be discussed. The clinical development program and safety for pure EPA VASCEPA will be reviewed. Visit the Amarin booth #414 for further information. Financial support for this program is provided by Amarin Pharma, Inc.

www.CardiometabolicHealth.org

Postgraduate Medicine is a peer-reviewed medical journal publishing research which supports primary care physicians in solving clinical problems and improving patient care. With our Accelerated Publication option, your research can be featured in Postgraduate Medicine in as little as: • 3-5 weeks with Fast Track publication • 7-9 weeks with Rapid Track publication To give your paper enhanced exposure to a targeted audience, consider publishing in Postgraduate Medicine’s second issue of 2019 entitled Cardiovascular Disease. The deadlines for submission are as follows: For Rapid Track papers: 20th November 2018 For Fast Track papers: 2nd January 2019

Why Accelerated Publication? • Planning ahead: Control your publication schedule with concrete timelines [and plan publication to coincide with anything from a thesis defense to a drug regulatory approval] • Unparalleled service: Fast Track is the fastest way to publish, quicker than any of our competitors • Increased visibility: The sooner your paper is published, the sooner it can be read and cited • Expert advice: Our experienced editors are on hand to assist with pre-submission advice, peer review guidance, and to provide tips on how to maximize the impact of your research • Recognized stamp of quality: Postgraduate Medicine is a MEDLINE-indexed journal with a rigorous and independent peer review process. It has an impact factor of 2.062* (© 2017 Thomson Reuters, Journal Citation Reports®)

www.tandfonline.com/ipgm

For pre-submission enquires please contact joseph.walsh@informa.com or submit your manuscript today at www.tandfonline.com/ipgm.

ASSOCIATION, MEDIA PARTNERS & SPONSORS PLATINUM MEDIA PARTNER The 2018 Cardiometabolic Health Congress gratefully acknowledges the following level sponsors:

ASSOCIATION PARTNERS

SILVER

American Medical Women’s Association American Society of Endocrine Physician Assistants Association of Black Cardiologists, Inc.

CLASSIC

Massachusetts Coordinating Body of AADE Society for the Study of Ingestive Behavior World Obesity National Stroke Association

PME (PROFESSIONAL MEDICAL EDUCATION)

Gaples Institute for Integrative Cardiology Granite State Diabetes Educators, Inc. University of Colorado Center for Women’s Health Research European Medical Journal

MEDIA PARTNERS Cardio Renal Medicine Mary Ann Liebert, Inc. Publishers Medical Sciences Nutrition Today PharmaVoice Postgraduate Medicine Educational Measures HTLH: The Future of Healthcare Cardiologists 2019 www.CardiometabolicHealth.org

13th Annual CMHC Accreditation ACTIVITY TITLE: 13th Annual Cardiometabolic Health Congress ACTIVITY DATE: October 24-27, 2018 | Boston, Massachusetts TARGET AUDIENCE The CMHC is designed for advanced level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk including cardiologists, endocrinologists, diabetologists, lipidologists, pharmacists, primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), and other allied health professionals. STATEMENT OF NEED/PROGRAM OVERVIEW The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care providers in the United States. Current estimates suggest approximately 23% - 38% of all U.S. adults have metabolic syndrome, a constellation of cardiometabolic risk factors, including excessive abdominal fat, insulin resistance, inflammation, dyslipidemia, and hypertension. Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes compared to those with no cardiometabolic risk factors. Cardiovascular disease currently affects approximately 83.6 million U.S. adults (> 1 in 3) and is the leading cause of U.S. deaths; however, this CVD burden is expected to increase. This sampling of sobering statistics points to a rapidly growing epidemic of cardiovascular and metabolic disease and calls to the forefront the need for medical education focused on all aspects of cardiometabolic risk. The Cardiometabolic Health Congress (CMHC) presents an especially valuable venue for this educational outreach bringing together faculty members from multiple disciplines, including cardiology, endocrinology, and primary care, to lead sessions that foster a collaborative, multidisciplinary approach to care. The 2018 CMHC will translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing cardiovascular and metabolic disorders. The goal is to provide the medical community with evidence-based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk. EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: 1. DEFINE the interrelationships among cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities 2. DESCRIBE evidence-based guideline recommendations based on recent clinical trials for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities 3. OUTLINE strategies, including biomarkers, imaging, and lifestyle modifications, for the prevention and risk assessment of cardiometabolic disease 4. IDENTIFY treatment regimens for cardiometabolic diseases based on efficacy and safety of current and new pharmacotherapies, and patient profiles and preferences to optimize patient outcomes 5. DISCUSS recent clinical trial data for emerging treatment options for cardiometabolic diseases in order to stay current with the most recent updates in the cardiometabolic field 6. CHOOSE communication strategies and patient education on new and emerging treatments, administration techniques, and technologies to implement into clinical practice in order to promote adherence to treatment regimens and provide patient-centered care SCOPE CERTIFICATION The World Obesity/Clinical Care committee decided that the further learning value, quality and structure of the 13th Annual Cardiometabolic Health Congress comply with Specialist Certification of Obesity Professional Education (SCOPE) principles. This event has been accredited with 4 SCOPE Points which count towards SCOPE Certification. SCOPE Certification is conferred by the World Obesity Federation and is the internationally-recognized standard of excellence in obesity management. SCOPE Certification is awarded to health professionals with obesity management experience who have earned 12 SCOPE points. For questions regarding SCOPE points, please contact info@cardiometabolichealth. org. PHYSICIAN ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION Global Education Group designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSING CONTINUING EDUCATION Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 21.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

www.CardiometabolicHealth.org

Pharmacotherapy hours are available for this activity, please visit https://www. cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html. PHARMACIST ACCREDITATION STATEMENT Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. CREDIT DESIGNATION Global Education Group designates this continuing education activity for 21.75 contact hour(s) (2.175 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge-based activity. Universal Activity Numbers (UAN) are listed below. Session Title UAN Pre-Conference “Women’s Health Summit: Cardiometabolic Health Across the Lifespan” Cardio-oncology: Overview and the Intersection Between Breast Cancer and Cardiovascular Disease 0530-9999-18-334-L01-P Cardiometabolic Risk in PCOS and Implications for Management 0530-9999-18-335-L01-P Impact of Pregnancy on CV Risk Factors and ASCVD Risk 0530-9999-18-336-L01-P Choosing Wisely: Contraception in Women with Cardiometabolic Risk 0530-9999-18-337-L01-P Updates on the Role of Postmenopausal Hormone Replacement Therapy/Women’s Health Summit Expert Panel Discussion and Q&A 0530-9999-18-338-L01-P Session I: Diabetes Management FDA Update and Late Breaking Trials 0530-9999-18-341-L01-P Keynote 0530-9999-18-342-L01-P Workshop: Insulin Biosimilars 0530-9999-18-343-L01-P So Many Options - Dispelling the Confusion About Insulins 0530-9999-18-344-L01-P Where Are We With Devices for Diabetes Management? 0530-9999-18-347-L01-P How Many GLP1 RAs Do We Need and Why? 0530-9999-18-348-L01-P Multidisciplinary Case Consults in Diabetes Management 0530-9999-18-349-L01-P Workshop: Real-world Digital Health Implementations to Improve Blood Pressure Control 0530-9999-18-350-L01-P Session II: Obesity and Lifestyle Management in Cardiovascular Disease Interventional Cardiology Delivered With a Fork 0530-9999-18-354-L01-P Updates on Metabolic Surgery 0530-9999-18-355-L01-P Obesity and Environmental Influence: The Big Picture 0530-9999-18-356-L01-P Workshop: Prevent Type 2 Diabetes with Digital Health: Effective and Realistic Solutions 0530-9999-18-357-L01-P Day to Day Management of Obesity in Clinical Practice 0530-9999-18-358-L01-P Session III: Dyslipidemia, Atherosclerosis, and Cardiovascular Disease Risk Reduction Targeting Inflammation: Updates on Pathophysiology and Clinical Outcomes 0530-9999-18-361-L01-P How Aggressively Do We Lower LDL-C and For Which Patients? 0530-9999-18-362-L01-P Don’t Hit the Snooze Button on Sleep: The Role of Sleep in Cardiometabolic Health 0530-9999-18-363-L01-P Risk Assessment for Global Cardiovascular Disease: Imaging and Biomarkers 0530-9999-18-364-L01-P Multidisciplinary Case Consults in Lipid Disorders 0530-9999-18-365-L01-P Session IV: Hypertension, Cardio-renal, and Heart Failure Overview of the New 2017 Hypertension Clinical Practice Guidelines 0530-9999-18-367-L01-P Comparing the Hypertension Guidelines - Where is the Equipoise? 0530-9999-18-368-L01-P Patient Cases: How would you change the management of hypertension based on the new guidelines? 0530-9999-18-369-L01-P Prevention of Heart Failure: The Next Frontier 0530-9999-18-370-L01-P Integration of Biomarkers and Prediction of AKI and Cardio-renal Outcomes in Clinical Practice 0530-9999-18-371-L01-P AKI and Heart Failure: How to manage compared to general population? 0530-9999-18-372-L01-P

Advanced CKD and Benefits from CVOTs 0530-9999-18-373-L01-P DIETICIAN ACCREDITATION STATEMENT Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 21.75 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012 GLOBAL CONTACT INFORMATION For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. INSTRUCTIONS TO RECEIVE CREDIT Learners may earn 21.75 credit hours by attending all Pre-Conference Sessions, General Sessions, and Workshops* and an additional 7.5 credit hours by attending a maximum of 6 CME Satellite Symposia; maximum credit hours possible is 29.25. *Registration is required for Workshops and seating is limited. If attending a CME Satellite Symposium, individual symposium evaluations are available to complete via the CMHC Mobile app, or by visiting https://eventmobi. com/cmhc2018/ and clicking on “CME Symposia Evaluations” under the Menu. Reminder emails will be sent each evening as well. For the overall conference evaluation, all attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check off which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018. FEE INFORMATION & REFUND/CANCELLATION POLICY There is a registration fee for this educational activity, registration information can be found online. DISCLOSURE OF CONFLICTS OF INTEREST Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/. DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. EDUCATIONAL GRANTS SUPPORT The 13th Annual CMHC is supported in part by an independent and unrestricted educational grants from Akcea Therapeutics, Amarin Pharma Inc., Novartis Pharmaceuticals Corporation, and Novo Nordisk. Please continue to check online for updates. For educational symposia support information, including accreditation, please visit the CME Symposia listings in this conference guide. This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

The Most Comprehensive Site for Cardiometabolic Health...

In addition to our Education Resource Center, featuring complimentary CME credits that can be taken exclusively online, we have added several new educational resources to our site: ranging from quizzes that challenge your knowledge of cardiometabolic health, to selected clinical pearls from our programming team & faculty members.

NEWSLETTER

THE MONTHLY BEAT

The Latest in Cardiometabolic Health

Our monthly newsletters feature popular blog posts, podcast episodes, scientific spotlights, and our most recent & upcoming events.

FACULTY SPOTLIGHT

Get to know our faculty members, and gain further information surrounding their backgrounds and expertise through multimedia videos.

CLINICAL CASE CHALLENGE Access the most clinically current information surrounding the practice of personalized, customized medicineâ&#x20AC;&#x201D; and its application to the most complex & challenging cardiometabolic patient cases.

View our collaboration with Frost & Sullivan, a global research and consulting organization, on the potential growth opportunities and trends in the global cardiometabolic diseases marketplace.

EDUCATION RESOURCE CENTER

The Latest in CardiometabolicRelated Guidelines and Clinical Pearls Dyslipidemia, Atherosclerosis, and CVD Risk Reduction

Diabetes Management

Hypertension and Heart Failure

Obesity and Lifestyle Management in CVD

Download our comprehensive list of the latest guidelines related to cardiometabolic health, featuring clinical pearls in cardiometabolic diagnosis, treatment, and prevention.

Our journal is a literary publication that features academic clinical articles, interviews with keynote faculty members, patient spotlights, and need-to-know information in cardiometabolic care.

Our Education Resource Center offers CME credits that can be taken exclusively online, all of which focus on the most clinically current topics in cardiometabolic care.

www.cardiometabolichealth.org

Learn about cardiometabolic risk factors & prevention methods through our interactive challenge quizzes.

CME Breakfast Symposium A

THURSDAY, OCTOBER 25

6:30 – 7:45 AM | CONSTITUTION BALLROOM

The Role of CGM in Individualization of T2DM Management Measuring HbA1c has been the method of choice to assess glucose control; however, this method does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications. Self-monitoring of blood glucose (SMBG), although beneficial in glycemic control, is associated with low

patient adherence. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations.

PHYSICIAN ACCREDITATION STATEMENT

PHARMACIST ACCREDITATION STATEMENT

INSTRUCTIONS TO RECEIVE CREDIT

CREDIT DESIGNATION

1. Please complete the evaluation survey specific to this symposium. Symposium evaluations are available via the CMHC Mobile app or by visiting https://eventmobi.com/cmhc2018/ and clicking on “CME Symposia Evaluations” under the Menu. Reminder emails will be sent each evening as well.

DIETICIAN ACCREDITATION STATEMENT

2. All attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form.

GLOBAL CONTACT INFORMATION

Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacotherapy hours are available for this activity, please visit https://www. cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html.

www.CardiometabolicHealth.org

To maximize the utility of CGM in T2DM management, this educational activity will focus on the latest

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Numbers (UAN): 0530-9999-18-339-L01-P Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012 For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

evidence-based studies, barriers, recommendations, as well as current and emerging CGM technologies aimed at maintaining glycemic goals and decreasing long-term complications of T2DM. Expert faculty will also provide guidance on the applications of CGM in the professional and personal setting with the aid of video animation.

To claim credit for this CME Symposium, please review the following 2-step process:

FACULTY

The Role of CGM in Individualization of T2DM Management

Anne L. Peters, MD (Chair)

Irl B. Hirsch, MD

Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California Los Angeles, CA

Professor of Medicine Diabetes Treatment and Teaching Chair University of Washington Medical Center Medical Director UWMC Diabetes Care Center Seattle, WA

LEARNING OBJECTIVES After completing this activity, the participant should be better able to:

• Review the latest evidence on the use of CGM technology in T2DM management • Recognize new and emerging CGM technologies • Identify how current and emerging CGM technologies can be used to improve outcomes for patients with T2DM

This satellite symposium is supported by educational grants from Dexcom, Inc. and Medtronic.

Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for attending the 13th Annual Cardiometabolic Health Congress. Registration information can be found online at https://www.cardiometabolichealth.org/2018/boston-13th-annual.html

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in

AGENDA

• Describe the latest published guidelines and recommendations for the use of CGM

6:30 - 6:35 am

Welcome and Introductions Anne L. Peters, MD (Chair)

6:35 – 6:50 am

T he Role of CGM in the Individualization of Type 2 Diabetes Management Anne L. Peters, MD (Chair)

6:50 – 7:10 am

Current Evidence and Practical Issues for CGM Use in T2D Irl B. Hirsch, MD

7:10 – 7:30 am

Diving Deeper: Current and Emerging CGM Devices Irl B. Hirsch, MD

7:30 – 7:35 am

Clinician and Patient Education and Training for CGM Anne L. Peters, MD (Chair)

7:35 – 7:45 am

Conclusions and Audience Q&A All Faculty

the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

CME Breakfast Symposium B

THURSDAY, OCTOBER 25 6:30 – 7:45 AM | GRAND BALLROOM

Non-Medical Switching, Barriers and Consequences During this program, Utilization Management (UM) processes will be explored. Prior Authorization (PA) and Step Therapy will first be defined and discussed, with examples from the literature demonstrating the prevalence and consequences of these processes. The dominant part of this program will focus on non-medical

PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

switching. Its definition, prevalence, healthcare burden, and health consequences will be examined. Emphasis will be on nonmedical switching in atrial fibrillation (Afib) and congestive heart failure (CHF). Related literature for all aspects of the program will be cited.

PHARMACIST ACCREDITATION STATEMENT

INSTRUCTIONS TO RECEIVE CREDIT

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

GLOBAL CONTACT INFORMATION

Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia.

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Numbers (UAN): 0530-9999-18-340-L01-P Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012 For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

To claim credit for this CME Symposium, please review the following 2-step process:

FACULTY

Non-Medical Switching, Barriers and Consequences

Seth J. Baum, MD, FASPC (Chair) Immediate Past-President, American Society for Preventive Cardiology Excel Medical Clinical Trials, LLC Founder, Chief Medical Officer Clinical Affiliate Professor of Biomedical Science Department of Integrated Medical Sciences,

Kim Newlin, NP, CNS, FPCNA, FAHA

Florida Atlantic University Charles E. Schmidt College of Medicine Medical Director, Women’s Preventive Cardiology Christine E. Lynn Women’s Health & Wellness

Advanced Practice Nurse Clinical Manager Sutter Health/Preventive Cardiovascular Nurses Association Sutter Roseville Medical Center Roseville, CA

Institute Boca Raton Regional Hospital Boca Raton, FL

LEARNING OBJECTIVES After completing this activity, the participant should be better able to: • Understand past ASPC efforts to improve patient access to mediations • Define the terms Utilization Management (UM), Prior Authorization (PA), step therapy, and non-medical switching • Cite relevant publications related to the program’s subject matter • Understand adverse consequences that can result from various UM practices, including non-medical switching • Understand the patient’s perspective by hearing patient-stories about non-medical switching • Understand and utilize resources to improve patient access to prescribed medications This satellite symposium is supported by educational grants from BMS Pfizer Alliance and Janssen Pharmaceuticals, Inc.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Maggie Kincaid; Stacy Manthos all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLAIMER

DISCLOSURE OF UNLABELED USE

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and the American Society for Preventative Cardiology.

www.CardiometabolicHealth.org

CME Lunch Symposium A

THURSDAY, OCTOBER 25 12:10 – 1:25 PM | GRAND BALLROOM

Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes throught a 20 years’ duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors. Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published data from clinical

PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

The University of Cincinnati designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

trials assessing cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists (RAs) show positive affects on the development and progression of DKD. This symposium will utilize interactive infographics to provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs.

Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacotherapy hours are available for this activity, please visit https:// www.cardiometabolichealth.org/2018/boston-13th-annual-accreditation. html.

#GE012

PHARMACIST ACCREDITATION STATEMENT

UNIVERSITY OF CINCINNATI CONTACT INFORMATION

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE)

Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider

For information about the accreditation of this program, please contact UC at 513-558-7277 or uc-cloudcme@ucmail.uc.edu.

INSTRUCTIONS TO RECEIVE CREDIT

FACULTY

Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Matthew R. Weir, MD (Chair)

Robert D. Toto, MD

Lance Sloan, MD, FACE, FASN

Professor and Director Division of Nephrology University of Maryland School of Medicine Baltimore, MD

Professor of Medicine Associate Dean for Clinical and Translational Research University of Texas Southwestern Medical Center Dallas Dallas, TX

Clinical Assistant Professor - UTMB Galveston, TX Medical Director of The Texas Institute for Kidney and Endocrine Disorders - Lufkin, TX Medical Director of HC Polk Education Center - Lufkin, TX Medical Director of SNG Dialysis - Lufkin, TX

LEARNING OBJECTIVES

12:10 – 12:15pm Welcome and Introduction Matthew R. Weir, MD (Chair)

After completing this activity, the participant should be better able to:

12:15 – 12:25 pm I dentifying DKD in Patients with T2DM: Causes of and Risk Factors Matthew R. Weir, MD (Chair)

• Review the most current T2DM algorithms and guidelines for the individualized treatment of complex patients, specifically those with DKD • Summarize the mode of action and effects of GLP-1 RAs and SGLT2 inhibitors on renal physiology in patients with T2DM and DKD • Develop management plans for T2DM patients that consider the recently discovered renal effects of SGLT2 inhibitors and GLP-1 RAs This satellite symposium is supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. and by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. 2. All attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

AGENDA

• Describe the relationship between T2DM, hypertension, and cardiorenal syndrome

12:25 – 12:35 pm Navigating the Guidelines for Treatment of T2DM Patients with DKD Robert D. Toto, MD 12:35 – 12:50 pm SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes Lance Sloan, MD, FACE, FASN 12:50 – 1:10 pm

Patient Case Study and Expert Roundtable All Faculty

1:10 – 1:20 pm

Audience Q&A All Faculty

1:20 – 1:25 pm

Conclusions Matthew R. Weir, MD (Chair)

DISCLOSURE OF CONFLICTS OF INTEREST

The University of Cincinnati requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the University of Cincinnati for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams; Bruce Gebhardt, MD; Susan P. Tyler, M.Ed., CMP, CHCP, FACEHP; Barb Forney all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLOSURE OF UNLABELED USE

faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by The University of Cincinnati and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ACCME credit. This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ANCC and ACPE credit.

www.CardiometabolicHealth.org

CME Lunch Symposium B

THURSDAY, OCTOBER 25

12:10 – 1:25 PM | CONSTITUTION BALLROOM

Advances in HFpEF: Addressing Diagnostic and Treatment Challenges Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have

PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Pharmacotherapy hours are available for this activity, please visit https://www.cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html.

www.CardiometabolicHealth.org

contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to manage HFpEF. This educational activity will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

To claim credit for this CME Symposium, please review the following 2-step process: 1. Please complete the evaluation survey specific to this symposium. Symposium evaluations are available via the CMHC Mobile app or by visiting https://eventmobi.com/cmhc2018/ and clicking on “CME Symposia Evaluations” under the Menu. Reminder emails will be sent each evening as well. 2. All attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will

FACULTY

Advances in HFpEF: Addressing Diagnostic and Treatment Challenges

JoAnn Lindenfeld, MD (Chair)

Keith C. Ferdinand, MD, FACC, FAHA

Director, Heart Failure and Transplant Professor of Medicine Vanderbilt University School of Medicine Nashville, TN

Alanna A. Morris, MD Assistant Professor of Medicine, Division of Cardiology Emory University Clinical Cardiovascular Research Institute Atlanta, GA

Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

LEARNING OBJECTIVES 12:10 – 12:15 pm Welcome and Introduction JoAnn Lindenfeld, MD (Chair)

After completing this activity, the participant should be better able to: • Employ current and emerging approaches and tools to diagnose HFpEF

12:15 – 12:30 pm Diagnosis of HFpEF JoAnn Lindenfeld, MD (Chair)

• Recognize current gaps in the guidelines for the treatment of HFpEF • Interpret results from clinical trials for emerging evidence-based therapies for patients with HFpEF • Outline practices and resources aimed to improve hospital readmission rates for patients with HFpEF

This satellite symposium is supported by an educational grant from Novartis Pharmaceuticals Corporation.

be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is a registration fee for attending the 13th Annual Cardiometabolic Health Congress. Registration information can be found online at https:// www.cardiometabolichealth.org/2018/boston-13th-annual.html

DISCLOSURE OF CONFLICTS OF INTEREST

AGENDA

• Identify current treatment guideline recommendations for HFpEF

12:30 – 12:50 pm The Current State of Pharmacotherapies Keith C. Ferdinand, MD 12:50 – 1:05 pm Decreasing Hospital Readmission Rates for HFpEF Patients Alanna A. Morris, MD 1:05 – 1:20 pm Case Study and Audience Q&A: Diagnosis and Treatment of HFpEF All Faculty 1:20 – 1:25 pm

Conclusions JoAnn Lindenfeld, MD (Chair)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLOSURE OF UNLABELED USE

DISCLAIMER

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

CME Dinner Symposium

THURSDAY, OCTOBER 25

6:15 – 7:30 PM | CONSTITUTION BALLROOM

Mastering the Prior Authorization Process to Meet Patient Needs The prior authorization (PA) process is often resourceintensive for medical practices. A 2016 American Medical Association (AMA) survey of physicians who regularly complete PAs found that, in combination with their staff members, the providers spent an average of 16.4 hours per week processing PAs. While estimates of the per-physician financial burden of PA and interaction with insurance companies have varied widely, all have found that those costs amount to thousands of dollars per year. The goal of the

live symposium is to provide learners with real-life solutions and resources for streamlining the PA process in their practices, with the goal of reducing the associated burdens on healthcare providers, minimizing related stress for patients, and preserving time for direct patient care.

PHYSICIAN ACCREDITATION STATEMENT

Pharmacotherapy hours are available for this activity, please visit https://www. cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html.

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

Prior to this educational activity, an infographic overview outlining recommendations and resources for streamlining the PA process in clinical practice

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

was provided to learners. As part of the infographic review, learners were also able to submit particularly challenging patient cases associated with PA, or common challenges endured during the PA process. The infographic primer will be briefly reviewed and the cases will be addressed by the expert faculty during the live symposium. An advocate for the Doctor-Patients Rights Project will also share their mission and provide a challenging experience encountered during the PA process.

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

Pamela B. Morris, MD (Chair)

Christie M. Ballantyne, MD

Director, Seinsheimer Cardiovascular Health Program Co-Director, Women’s Heart Care Medical University of South Carolina Charleston, SC

Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology

Kim K. Birtcher, PharmD

Matthew Stryker, PharmD, BCACP, CLS

Clinical Professor University of Houston College of Pharmacy Houston, TX

Assistant Professor Albany College of Pharmacy and Health Sciences Albany Medical Center – Division of Community Endocrinology Albany, NY

Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Houston, TX

LEARNING OBJECTIVES

6:15 – 6:20 pm

Welcome and Introduction Pamela B. Morris, MD (Chair)

After completing this activity, the participant should be better able to:

6:20 – 6:30 pm

Infographic Primer Review Pamela B. Morris, MD (Chair)

• Describe the burden of the prior authorization process on physicians and staff in clinical practice and patient outcomes • Identify strategies and resources that reduce the time and expenses associated with submissions for prior authorization • Develop prior authorization processes to gain drug and procedure approval for patients in a timely manner

This satellite symposium is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals and in partnership with The Doctor-Patient Rights Project Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are

AGENDA

FACULTY

Mastering the Prior Authorization Process to Meet Patient Needs

6:30 – 7:00 pm Interactive Patient Case Consults: Tips and Strategies to Obtain PA Pamela B. Morris, MD (Chair); Christie M. Ballantyne, MD; Kim K. Birtcher, PharmD 7:00 – 7:15 pm Doctor-Patient Rights Project: Patient Advocate Presentation Matthew Stryker, PharmD 7:15 – 7:25 pm

Q&A Moderator: Pamela B. Morris, MD (Chair) Expert Panel: All faculty

7:25 – 7:30 pm

Conclusions Pamela B. Morris, MD (Chair)

in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF UNLABELED USE

JOINT PROVIDERSHIP STATEMENT

DISCLAIMER

www.CardiometabolicHealth.org

CME Breakfast Symposium A

FRIDAY, OCTOBER 26

6:30 – 7:45 AM | CONSTITUTION BALLROOM

The ABC Access Program: Overcoming Barriers to Access of Newer Cardiovascular Agents for High-Risk and Minority Despite advances in medical therapies and new treatment modalities for patients with or at risk for cardiovascular disease, health equality and access to care remain significant areas of concern. Two associations have set their goals to address these clinical barriers. The Association of Black Cardiologists (ABC) has set its mission to address critical issues in a changing PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

health care landscape by revealing disparities faced by minorities and high-risk patients and promulgating solutions to diminished access, especially to newer medications and therapies. The FH Foundation is dedicated to promoting the understanding of Familial Hypercholesterolemia (FH) in the medical community and public domain, examining gaps in care for those living with FH, and improving Pharmacotherapy hours are available for this activity, please visit https://www. cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

adherence to guideline-recommended treatments for FH. During this live symposium, faculty will discuss ongoing initiatives to overcoming barriers to access, and provide overviews of both the Access to Health Care Initiative of the Association of Black Cardiologists and the Cascade Registry from the FH Foundation. Challenging clinical patient cases will also be presented to demonstrate how to apply these solutions to real-world clinical scenarios. GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

FACULTY

The ABC Access Program: Overcoming Barriers to Access of Newer Cardiovascular Agents for High-Risk and Minority

Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

Deirdre J. Mattina, MD

Catherine Davis Ahmed, MBA

Senior Staff Physician, Division of Cardiology Director, Women’s Heart Center Henry Ford Hospital Detroit, MI

Vice President, Policy and Outreach The FH Foundation Pasadena, CA

LEARNING OBJECTIVES

6:30 – 6:35 am

Welcome and Introductions Keith C. Ferdinand, MD (Chair)

After completing this activity, the participant should be better able to:

6:35 – 6:50 am

Ongoing Initiatives to Overcome Barriers to Access Deirdre J. Mattina, MD

6:50 – 7:00 am

The ABC Access Program: Actions Taken, Current Status and Future Considerations Keith C. Ferdinand, MD (Chair)

7:00 – 7:10 am

FH Patient Case: What’s Being Done Catherine Davis Ahmed, MBA

• Summarize the barriers to access of quality care for African Americans and the solutions proposed in the ABC Access Initiative to improve access, especially to newer therapies • Identify evidence-based treatment recommendations to aggressively manage cardiovascular risk factors in African Americans, thereby reducing the incidence and consequence of heart failure

This satellite symposium is supported by an educational funding donation provided by Amgen and in partnership with the Association of Black Cardiologists, Inc (ABC).

Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are

AGENDA

• Discuss the disproportionate burden of heart disease and stroke within the African American population and the mission of the ABC Access Initiative

7:10 – 7:30 am Real World Approaches to Access: A Clinician’s Perspective Case Presenters: Deirdre J. Mattina, MD and Keith C. Ferdinand, MD Panel: All faculty 7:30 – 7:45 am

Panel Discussion, Q&A, and Conclusions All faculty

associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

JOINT PROVIDERSHIP STATEMENT DISCLOSURE OF UNLABELED USE

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

CME Breakfast Symposium B

FRIDAY, OCTOBER 26 6:30 – 7:45 AM | GRAND BALLROOM

Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice Death from CV disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death. Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM, and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. Moreover, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of

PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

evidence suggests on the effectiveness of several antihyperglycemic agents to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM. In this symposium, experts will utilize a unique, infographic teaching format to review the latest cardiovascular outcomes studies of current antihyperglycemic therapies and compare both risks and benefits, as well as how to incorporate them into an individualized treatment plan for clinicians who treat patients with T2DM, and are also at a high risk for CVD.

Pharmacotherapy hours are available for this activity, please visit https:// www.cardiometabolichealth.org/2018/boston-13th-annual-accreditation. html.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

Provider #GE012

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice

Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics

Deepak L. Bhatt, MD, MPH Professor of Medicine Harvard Medical School Executive Director

Charles A. Boettcher II Chair in Atherosclerosis Director, T32 in Obesity and Cardiovascular Disease University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Aurora, CO

Harold E. Bays, MD

Interventional Cardiovascular Programs Brigham and Women’s Hospital Heart and Vascular Center Boston, MA

Lawrence Blonde, MD

LEARNING OBJECTIVES After completing this activity, the participant should be better able to: • Describe comorbidities of CVD among patients with T2DM, including the prevalence and burden • Summarize current and emerging CV outcomes trials on SGLT2 inhibitors and GLP1-RAs in T2DM patients • Incorporate evidence from recent CVOTs to develop T2DM treatment plans that improve glycemic control and reduce CV risk when appropriate based on guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences This satellite symposium is supported by educational grants from AstraZeneca and Novo Nordisk. Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia. Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are

AGENDA

FACULTY

Robert H. Eckel, MD

Medical Director/President Louisville Metabolic and Atherosclerosis Research Center, Inc. Louisville, KY

Director, Ochsner Diabetes Clinical Research Unit Frank Riddick Diabetes Institute Department of Endocrinology Ochsner Medical Center New Orleans, LA

6:30 – 6:35 am

Welcome and Introductions Robert H. Eckel, MD (Chair)

6:35 – 6:40 am

CV Comorbidities in T2DM Patients Deepak L. Bhatt, MD, MPH

6:40 – 7:00 am

Review of Recent CVOTs Results and Clinical Implications Lawrence Blonde, MD

7:00 – 7:15 am

Individualization of Treatment in T2DM Patients with CVD Harold E. Bays, MD

7:15 – 7:30 am

CVOT Data in Your Clinical Practice: Patient Case Presenter: Deepak L. Bhatt, MD, MPH Panel: Robert H. Eckel, MD (Chair); Harold E. Bays, MD; Lawrence Blonde, MD

7:30 – 7:45 am

Conclusions and Audience Q&A All Faculty

information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF UNLABELED USE

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

DISCLAIMER

JOINT PROVIDERSHIP STATEMENT

www.CardiometabolicHealth.org

CME Lunch Symposium A

FRIDAY, OCTOBER 26 12:00 – 1:15 PM | GRAND BALLROOM

Identifying, Diagnosing and Managing Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life Iron deficiency (ID) affects up to one-third of the world’s population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and

PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID, yet the condition is under-recognized and untreated in most patients. During this symposium, experts will provide participants with data from recent and ongoing trials of iron

www.cardiometabolichealth.org/2018/boston-13th-annual-accreditation. html.

PHARMACIST ACCREDITATION STATEMENT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT

FACULTY

Identifying, Diagnosing and Managing Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life

Eldrin F. Lewis, MD, MPH (Chair)

Akshay S. Desai, MD, MPH

Gurusher S. Panjrath MD, FACC, FAHA

Director Cardiovascular Clerkships and STARS Research Program, Brigham and Women’s Hospital BWH Clinical Endpoints Center Associate Professor of Medicine, Harvard Medical School Boston, MA

Associate Professor of Medicine, Harvard Medical School Director, Cardiomyopathy and Heart Failure Advanced Heart Disease Section Cardiovascular Division Brigham and Women’s Hospital Boston, MA

Director, Heart Failure and Mechanical Circulatory Support Program Associate Professor of Medicine George Washington University School of Medicine Washington, DC

LEARNING OBJECTIVES After completing this activity, the participant should be better able to:

12:00 – 12:05 pm Welcome and Introduction Eldrin F. Lewis, MD, MPH (Chair)

• Describe the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life

• Discuss the updated ACC/AHA/HFSA recommended guidelines for the management of iron deficiency in patients with HF • Review evidence from major clinical trials assessing the efficacy and safety of iron supplementation in HF patients to improve patient outcomes and reduce HF hospitalizations

AGENDA

• Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID

12:05 – 12:30 pm Iron Deficiency in Heart Failure Gurusher S. Panjrath MD, FACC, FAHA 12:30 – 12:55 pm Treatment of Anemia: Evidence from Recent and Ongoing Clinical Trials Akshay S. Desai, MD 12:55 – 1:10 pm

Challenging Patient Case and Audience Q&A Case Presenter: Eldrin F. Lewis, MD, MPH (Chair) Panel: Akshay S. Desai, MD; Gurusher S. Panjrath, MD

1:10 – 1:15 pm

Conclusions Eldrin F. Lewis, MD, MPH (Chair)

This satellite symposium is supported by an educational grant from American Regent.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLOSURE OF UNLABELED USE

information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

CME Lunch Symposium B

FRIDAY, OCTOBER 26

12:00 – 1:15 PM | CONSTITUTION BALLROOM

New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia Due to the progressive nature of type 2 diabetes mellitus (T2DM), insulin is typically initiated when patients are unable to achieve and maintain glycated hemoglobin (HbA1c) target levels with lifestyle changes and addition of one or more antidiabetic drugs to the treatment regimen. However, the initiation and intensification of diabetes treatment with insulin is often delayed in many patients due to clinical inertia and fears of hypoglycemia. Intensive insulin regimens often cause a higher risk of hypoglycemia; approximately 7%

to 15% of insulin-treated patients experience at least one annual episode of hypoglycemia, and 1 to 2% have severe hypoglycemia.

PHYSICIAN ACCREDITATION STATEMENT

PHARMACIST ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CMHC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

During this live symposium, faculty will address the barriers to intensifying T2DM treatment with insulin, including clinical inertia and the risk of hypoglycemia, current treatment recommendations for glycemic control in T2DM, and efficacy and safety data for the newer fixed-ratio combinations to achieve glycemic

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

UNIVERSITY OF CINCINNATI CONTACT INFORMATION For information about the accreditation of this program, please contact UC at 513-558-7277 or uc-cloudcme@ucmail.uc.edu.

control and reduce hypoglycemic risk. Case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and then immediately observe the consequences of their decisions—without risk. Learners will receive the benefit of engaging in deliberate practice in an environment that is safe, consistent, convenient and individualized to improve their management of patients with T2DM and risk of hypoglycemia. INSTRUCTIONS TO RECEIVE CREDIT

Robert E. Ratner, MD (Chair)

Robert H. Eckel, MD

Professor of Medicine Georgetown University School of Medicine Washington, DC

Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Division of Cardiology Professor of Physiology and Biophysics

Davida F. Kruger, MSN, APNBC, BCADM

Deborah J. Wexler, MD, MSc

Massachusetts General Hospital Boston, MA

Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease Detroit, MI

Associate Professor of Medicine, Harvard Medical School Associate Clinical Chief, MGH Diabetes Center

LEARNING OBJECTIVES

12:00 – 12:05 pm Welcome and Introduction Robert E. Ratner, MD (Chair)

After completing this activity, the participant should be better able to:

12:05 – 12:10 pm Treatment Intensification: The Earlier the Better Robert E. Ratner, MD (Chair)

• Discuss strategies to overcome barriers to insulin intensification in T2DM, including clinical inertia and the risk of hypoglycemia

12:10 – 12:25 pm Interactive Patient Case in DecisionSim Attendees

• Develop individualized T2DM therapy based on a clinical understanding of the features of oral and injectable antidiabetic medications and patient-specific needs and preferences

12:25 – 12:40 pm T2DM Treatment: A Stepwise Approach Deborah J. Wexler, MD, MSc

• Outline the safety, efficacy, and pharmacological data on new insulin therapies and fixed-ratio GLP-1RA/basal insulin combinations

AGENDA

FACULTY

Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice

12:40 – 12:50 pm New Treatments on the Block: Fixed-ratio GLP-1RA/Basal Insulin Combinations Robert H. Eckel, MD

• Implement patient education and patient-prescriber communication strategies to aid patients in overcoming concerns about insulin intensification and fear of injections, thus increasing patient adherence to therapy and improving clinical outcomes

12:50 – 1:00 pm

Improving Adherence: Reducing Patient and Provider Fears to Treatment Intensification Davida F. Kruger, MSN, APNBC, BCADM

1:00 – 1:10 pm

DecisionSim Discussion and Audience Q&A Moderator: Robert H. Eckel, MD Panel: All Faculty

This satellite symposium is supported by an educational grant from Sanofi US.

1:10 – 1:15 pm

Conclusions Robert E. Ratner, MD (Chair)

CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before December 23, 2018.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

partner have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams; Bruce Gebhardt, MD; Susan P. Tyler, M.Ed., CMP, CHCP, FACEHP; Barb Forney all have nothing to disclose. For faculty disclosures, please visit https://eventmobi.com/cmhc2018/.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Cincinnati and CMHC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

JOINT PROVIDERSHIP STATEMENT

DISCLAIMER

Participants have an implied responsibility to use the newly acquired

www.CardiometabolicHealth.org

CME Breakfast Symposium

SATURDAY, OCTOBER 27 6:30 – 7:45 AM | GRAND BALLROOM

Finding the Balance: Treatment and Management of Hyperkalemia in Patients with Heart Failure and Chronic Kidney Disease Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility PHYSICIAN ACCREDITATION STATEMENT

PHYSICIAN CREDIT DESIGNATION

NURSING CONTINUING EDUCATION

www.CardiometabolicHealth.org

of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. This symposium will provide clinicians with clinical evidence on the new and potential therapies for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward providing appropriate management for hyperkalemic patients with CKD, diabetes mellitus (DM), and/or HF by assessing risk profiles and customizing regimens based on individual patient needs.

Pharmacotherapy hours are available for this activity, please visit https:// www.cardiometabolichealth.org/2018/boston-13th-annual-accreditation.html.

GLOBAL CONTACT INFORMATION

PHARMACIST ACCREDITATION STATEMENT

INSTRUCTIONS TO RECEIVE CREDIT

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION

DIETICIAN ACCREDITATION STATEMENT

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. To claim credit for this CME Symposium, please review the following 2-step process: 1. Please complete the evaluation survey specific to this symposium. Symposium evaluations are available via the CMHC Mobile app or by visiting https://eventmobi.com/cmhc2018/ and clicking on “CME Symposia Evaluations” under the Menu. Reminder emails will be sent each evening as well. 2. All attendees will be emailed the CMHC Online Evaluation link by Monday, October 29, 2018. The evaluation will request that you check which sessions (Pre-Conference, General Sessions, Workshops, and CME Symposia) you have attended. The evaluation must be completed by November 19, 2018. CME/CE Certificates will be available for print immediately upon completion of the online evaluation form. Attendees may earn a maximum of 29.25 credit hours by attending all Pre-Conference Sessions, General Sessions, Workshops, and 6 CME Symposia.

FACULTY

Keith C. Ferdinand, MD, FACC, FAHA

George L. Bakris, MD (Chair) Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL

Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

LEARNING OBJECTIVES After completing this activity, the participant should be better able to: • Describe patient populations at the highest risk for hyperkalemia • Assess the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies based on evidence-based guideline recommendations for HF management and appropriate monitoring for renal function and hyperkalemia • Develop appropriate treatment regimens for hyperkalemia in patients with HF and CKD based on the Identify the efficacy, safety, and mechanisms of action of current and emerging therapies This satellite symposium is supported by an educational grant from Relypsa.

FEE INFORMATION & REFUND/CANCELLATION POLICY

DISCLOSURE OF CONFLICTS OF INTEREST

AGENDA

FACULTY

Finding the Balance: Treatment and Management of Hyperkalemia in Patients with Heart Failure and Chronic Kidney Disease

6:30 – 6:35 am

Welcome and Introduction George L. Bakris, MD (Chair)

6:35 – 7:00 am

Hyperkalemia: Risk Factors and Best Practices for Treatment and Management in Patients with CHF and CKD Keith C. Ferdinand, MD

7:00 – 7:15 am

Current and Emerging Treatment Options for Hyperkalemia George L. Bakris, MD (Chair)

7:15 – 7:30 am

Interactive Discussion: Patient Case Scenario Presenter: George L. Bakris, MD (Chair) Faculty Panel: Keith Ferdinand, MD

7:30 – 7:45 am

Conclusions and Audience Q&A George L. Bakris, MD (Chair)

information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF UNLABELED USE

JOINT PROVIDERSHIP STATEMENT

This educational activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing

DISCLAIMER

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

www.CardiometabolicHealth.org

Could your patients be at risk for

Vitamin D Deficiency? Recent evidence suggests that vitamin D intake well above current recommendations may be necessary to achieve targeted serum 25(OH)D levels. DEFICIENCY

10 to 15 ng/ml

INSUFFICIENCY

15 to 30 ng/ml

MINIMAL TARGET

30 ng/ml

OPTIMAL

40 to 70 ng/ml

Based on the recommendations of the Point Institute of Nutraceutical Research

Vitamin D2 (Ergocalciferol) vs. Vitamin D3 (Cholecalciferol) Vitamin D3 is the bioidentical form of vitamin D, which is synthesized in the skin when exposed to sunlight. Recent research from human clinical trials found: â&#x20AC;˘ Vitamin D3 is approximately 87% more potent in raising and maintaining serum 25(OH)D concentrations â&#x20AC;˘ Vitamin D3 produces two to threefold greater storage of vitamin D than vitamin D2

Stop by Booth 514! The first 50 visitors will receive a

15-count box of Vitamin D3 50,000 IU These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOIN US F OR THE AS P C T O W N H ALL

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App & More Join us as we discuss how to gain access to PCSK9 Inhibitors and learn about the revolutionary mobile application, created by the American Society for Preventive Cardiology, to overcome the hurdle in accessibility.

Wednesday, October 24 • 4:15-5:15 PM Republic Ballroom • Second Floor • Boston Sheraton Hotel

F A C U LT Y

DOWNLOAD THE ASPC MOBILE APP TODAY!

Seth J. Baum, MD, FASPC Immediate Past-President,

American Society for Preventive Cardiology

Howard Weintraub, MD, FASPC

Board Member, American Society for Preventive Cardiology

This activity is sponsored by Amgen Inc. and Sanofi Regeneron Pre-registration is not required.

All abstracts from the 13th annual CMHC will be published by Medical Sciences, an international open access journal providing a platform for advances in basic, translational, and clinical research.

SCIENTIFIC EXHIBIT HALL P001. Cardioprotective effect of liraglutide is amplified with anti-inflammatory and decreased brain natriuretic preptide levels, in addition to glycemia and body weight reduction. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Piljac A1, Jazbec A 2, Duvnjak L1, Ljubic S1 1. Clinical Hospital Merkur, University Clinic Vuk Vrhovac, Zagreb, Croatia; 2. University of Zagreb, Zagreb, Croatia

P002. Effect of Royal Jelly Intake on Serum Glucose, Apolipoprotein A-I (ApoA-I), Apolipoprotein B (ApoB) and ApoB/ApoA-I Ratios in Patients with Type 2 Diabetes: A Randomized, Double-Blind Clinical Trial Study. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Farzad Shidfar1,2, Basmeh Khoshpey1, Shima Djazayeri1, Fatemeh Amiri 1, Mojtaba Malek 2, Agha Fatemeh Hosseini 3 , Sharieh Hosseini 4, Shahrzad Shidfar5 1. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; 2. Cardiovascular Research Center, Institute of Endocrine and Metabolism, Iran University of Medical Sciences, Tehran, Iran; 3. Department of Statistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; 4.

Department of Applied Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran; 5. Worcester Memorial Hospital, University of Massachusetts, Worcester, Massachusetts, USA.

P003. Predictive value of epicardial fat volume for the presence of significant coronary artery Disease. Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Eltamawy K, Mostafa H, Ahmad Fouad D Assiut General Hospital (Ministry of Health), Assiut University Hospital, Qesm Than Asyut, Egypt

P004. Takotsubo Cardiomyopathy in Chronic Kidney Disease patients: A systematic review. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Kariyanna PT1, Borhanjoo P2, Jayarangaiah A 3, McFarlane S2 1. Division of Cardiovascular Disease, Department of Internal Medicine, SUNY Downstate, Brooklyn, N.Y. 2. Department of Internal Medicine, SUNY Downstate, Brooklyn, N.Y. 3. Department of Internal Medicine, Wake Forest University - Baptist Health system, Winston Salem, N.C.

P005. Type 2 diabetic patients and patients on basal supported oral therapy mainly benefit from introduction of insulin degludec. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Ljubic S1,2, Piljac A1, Jazbec A 2, Antal I1, Lea Duvnjak L1,2 1. Vuk vrhovac University Clinic, Merkur Clinical Hospital, Zagreb, Croatia; 2. University of Zagreb, Zagreb, Croatia.

P006. Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss Therapy: A MetaAnalysis. Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Kane JA, Munir I, Mehmood T, Kamran H, Yacoub M, Youssef I, Gustafson DR, McFarlane SI SUNY Downstate Medical Center, Brooklyn, NY.

P007. The effects of RYGB on tissue insulin sensitivity, beta cell function and post-meal glucose flux are maintained 7 years after surgery in both diabetic and non diabetic patients. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM M Palumbo1, B Astiarraga1, C Barbieri2, M Gaggini2, L Vecoli1, V Zampa3, M Anselmino5, A Mari2, A Gastaldelli4, S Camastra1. 1. Department of Clinical and Experimental Medicine, University of Pisa; 2. Institute of Clinical Physiology, CNR, Pisa; 3. Radiodiagnostic Unit, Santa Chiara Hospital Pisa; 4. Bariatric Surgery Unit, Santa Chiara Hospital Pisa; 5 CNR, Padua.

P008. Long-Term Effect of Patiromer for Hyperkalemia Treatment in Patients With HFmrEF and Diabetic Nephropathy on RAAS Inhibitors. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Pitt B1, Mayo M2, Garza D2, Arthur S2, Lainscak M3 1. University of Michigan School of Medicine, Ann Arbor, MI, United States; 2. Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, United States; 3. General Hospital Murska Sobota, Murska Sobota, Slovenia.

P010. Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction. Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Rozenbaum Z, Topilsky Y, Laufer-Perl M Department of Cardiology, Tel Aviv Medical Center, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University.

P011. Results of Intensive Weight Loss Program (IWLP) (non-surgical) in a primary care office. Comparison of IWLP and CDC Diabetes Prevention Program (CDC DPP). Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Ahmed M1, Rader A2 1. Activate Healthcare, 2010 N. Damen Ave., Suite F, Chicago, IL 60647; 2. Idaho Weight Loss, 801 N. Stilson Rd. #200, Boise, ID 83703.

P012. Lowered glucose levels and exogenous insulin requirements in T2DM and T1DM patients treated with oral insulin (ORMD-0801): Phase 2, randomized, placebo-controlled evaluations. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Kidron M, Homer K, Neutel J

P009. Effect of Patiromer on Serum Potassium in Hyperkalemic Patients With and Without Obesity: Pooled Results from the AMETHYST-DN, OPAL-HK and TOURMALINE Trials. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM Rossignol P1, Gross C2, Mayo M2, Warren S2, Yuan J2, Budden J2, Morales E3 1. Centre d’Investigations CliniquesPlurithématique, INSERM, Université de Lorraine, Nancy, France; 2. Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, United States; 3. Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain.

Oramed Pharmaceuticals, Jerusalem, Israel; Integrium, LLC, Cedar Knolls, NJ, USA; St. Joseph Hospital, Tustin, CA, USA.

P013. Assessment of Cardiovascular Disease Risk And Therapeutic Patterns Among Urban Black Rheumatoid Arthritis Patients. Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM McFarlane IM, Bhamra MS, Taklalsingh N, Kaplan I, Dellinger E, Smerling J, Lopez DL, Gondal I, Paltoo K, Trevisonno M SUNY Downstate Medical Center; Health + Hospitals Kings County, Brooklyn, NY.

P014. Comparative Effectiveness and Safety between Non-VKA Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients: A Dose Subgroup Analysis of the ARISTOPHANES Study. Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Lip GYH1, Keshishian A 2, Li X3, Hamilton M3, Masseria C4, Dhamane A 3, Luo X5, Mardekian J4, Friend K3, Nadkarni A 3, Pan X6, Baser O7, Deitelzweig S8 1. Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 2. STATinMED Research, Ann Arbor, MI, USA; 3. BristolMyers Squibb Company, Lawrenceville, NJ, USA; 4. Pfizer, Inc., New York, NY, USA; 5. Pfizer, Inc., Groton, CT, USA; 6. Bristol-Myers Squibb Company, Wallingford, CT, USA; 7. Columbia University, New York, NY, USA; 8. Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, LA, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.

P015. Differences in the Management of Acute Coronary Syndromes by Race and Proximity to Care in an Integrated Healthcare Delivery System in Northern Nevada. Friday, October 26, 2018, 10:00 – 11:00 AM, 2:20 - 3:20 PM Rowan C1, Metcalf J2, Grzymski J2, Mues KE3, Yedigarova L 3, Woo C 3, Williams KA4 1. Renown Institute for Heart & Vascular Health, Reno, NV; 2. Desert Research Institute, Las Vegas, NV; 3. Amgen Inc, Thousand Oaks, CA; 4. Rush University, Chicago, IL.

Proud Media Partner of the Cardiometabolic Health Congress

Live meeting coverage! Cardiology Today is reporting live from CMHC. Get up-to-the-minute news and perspective straight from the podium on Healio.com, the online home of Cardiology Today. In print and online, you’ll get the latest meeting coverage along with expert perspective from our renowned Editorial Board and other leading clinicians. Congenital heart disease and dementia 6

STEMI treatment delays 12

Business of Cardiology 15

Healio.com/Cardiology

Volume 21 • Number 4 APRIL 2018

Cardiology covered.

Carl J. Pepine, MD, Chief Medical Editor

Daily news

COVER STORY

Source: Sidney C. Smith Jr., MD, MACC, FAHA, FESC. Printed with permission.

Obesity slowly undoing progress made in decreasing CVD

Sidney C. Smith Jr., MD, MACC, FAHA, FESC, from University of North Carolina School of Medicine, said cardiologists should focus on lifestyle modifications to prevent CVD in patients with obesity.

HF AND TRANSPLANTATION All HF and Transplantation articles start on page 44

Although progress has been made in reducing BP and cholesterol in patients in the United States, obesity, a widespread condition, is halting that progress by increasing the risk for CVD. The prevalence of obesity has risen over the past 3 years, and more than one-third of U.S. adults is estimated to have obesity, according to a 2017 report from the National Forum for Heart Disease and Stroke Prevention. New data from the NHANES surveys showed that age-standardized prevalence of obesity among U.S. adults increased from 33.7% in 2007-2008 to 39.6% in 2015-2016. As obesity increases, medical expenditures for the treatment of obesity-related illnesses also rise. In a study published in Clinical Chemistry in 2018, medical expenditures in the United States increased by 29% from 2001 to 2015. “Even though we’re able to make headway in those other risk factors which improve CVD rates, because we, as a society, have not done as great a job at addressing obesity and diabetes, then that’s going to halt the Cover Story continues on page 10

MEETING NEWS: ACC

Neighborhood deprivation increases risk for HF

Participants from low-income populations who lived in the most deprived neighborhoods had an increased risk for HF, according to a study published in Circulation: Cardiovascular Quality and Outcomes. “There is existing evidence suggesting strong, independent associations between personal socioeconomic status — like education, income level and occupation — and risks of heart failure and many other chronic diseases,” Loren Lipworth, ScD, Neighborhood continues on page 45

SMART-DATE Analysis of the safety of 6-month vs. 12-month or longer DAPT in patients with ACS after receiving a second-generation drug-eluting stent. Design:

randomized, parallel-assignment, open-label

Patients:

2,712

Centers: Country:

31 South Korea

All ACC Meeting News articles start on page 22

RESULTS: See page 17

ODYSSEY Outcomes: Alirocumab lowers CV events in ACS population Reducing LDL to very low levels with the PCSK9 inhibitor alirocumab lowered risk for major adverse CV events and all-cause mortality in patients with ACS on statin therapy, according to anticipated results of the ODYSSEY Outcomes trial. For the primary outcome of major adverse CV events, defined as CHD death, nonfatal MI, ischemic stroke or unstable angina requiring hospitalization, alirocumab (Praluent, Sanofi/Regeneron) conferred a 15% risk reduction compared with placebo (HR = 0.85; 95% CI, 0.78-0.93; absolute risk reduction = 1.6%). All 18,924 patients (mean age, 58 years; 25% women) were followed for at least 2 years, with 44% followed for at least 3 years (median, 2.8 years). Patients assigned alirocumab also had reduced risk for all-cause mortality (HR = 0.85; 95% CI, 0.73-0.98;

Meeting coverage

TRIAL SCORECARDS All Intervention articles start on page 12

Physician perspective

ARRHYTHMIA DISORDERS

absolute risk reduction = 0.6%) compared with those assigned placebo, Philippe Gabriel Steg, MD, FESC, FACC, director of the coronary care unit in the cardiology department at Hôpital Bichat, Paris, professor of cardiology at the Université Paris – Diderot, and Cardiology Today’s Intervention Editorial Board Member, said during a presentation. Aside from injection-site reactions, alirocumab was not linked to excess adverse events compared Philippe Gabriel Steg with placebo, Steg said. The ODYSSEY Outcomes patient population was different than patients enrolled in the FOURIER outcomes

All Arrhythmia Disorders articles start on page 40

AF-stroke relationship strongest in black patients Among patients with atrial fibrillation, black patients had increased risk for having an ischemic stroke before or after an AF diagnosis compared with white patients, according to a study published in HeartRhythm. Nearly half of ischemic strokes in patients with incident AF occurred before their diagnosis, according to the researchers. “To date, large phase-3 clinical trials that have evaluated the safety and efficacy of novel blood

CME

Relationship continues on page 40

ODYSSEY continues on page 22

IMAGING

VASCULAR MEDICINE

IN THE JOURNALS

Cardiac MRI appropriate for assessing mitral regurgitation

VIP-U: Psoriasis treatment reduces vascular inflammation

Cocaine use confers epicardial, microvascular disease

PAGE 39

PAGE 46

PAGE 47

Video

A SLACK Incorporated® publication

CT0418_1,10-11.indd 1

3/28/2018 8:45:47 AM

Healio.com/Cardiology 18-0803

Advancing Education in Cardiometabolic Disease

CMHC is excited to announce the second issue of Cardiometabolic Chronicle. This literary publication delivers the most current and relevant information in cardiometabolic health, and provides exclusive access to faculty spotlights, highlights on partner communications, and interviews with industry KOLs. Our first issue included a series of featured articles that focused on various aspects of cardiometabolic health, including critical updates surrounding the status of cardiovascular outcome trials for antidiabetic drugs, and education regarding type 2 diabetes and heart failure management. Other sections highlighted the most recently emerging advancements in the field of cardio-oncology, and news sections that reflected the most current events and highlights in the field of cardiometabolic health. Through expert and patient perspectives, highlights of past CMHC meetings, and literature scans, Cardiometabolic Chronicle will continue to reflect the constant evolution of the field.

CALL FOR SUBMISSIONS

Cardiometabolic Chronicle welcomes the submission of articles on the topic of cardiometabolic health and spanning a diverse range of content, including featured articles, opinions, clinical pearls, patient perspectives and more.

For more detailed information, please contact the journal at info@cardiometabolichealth.org.

www.cardiometabolichealth.org

How the Game Works As an attendee, you will receive a passport book with your registration materials onsite at the conference. To play: 1. Visit each booth listed on the passport. 2. Speak and engage with the exhibitor; take some time to view and learn from their demonstrations. 3. Receive a sticker from the exhibitor to add to their corresponding square on your passport. 4. Once you have filled ALL the squares on your passport, return your completed game card to the CMHC exhibit booth and you will be qualified to participate in the Grand Prize Drawing.

Exhibit Hall MacBook Pro -15-inch

Touch Bar and Touch ID 2.6GHz 6-Core Processor - 512GB Storage

Garmin Fenix 3 HR

Drawings for all prizes will take place during the Closing Reception on Friday, October 26th. Attendees must be present in the Exhibit Hall to qualify for the prize drawings.

Prize Drawings

23andMe DNA Test

Drawings for all prizes will take place during the Closing Reception on Friday, October 26th in the Exhibit Hall. Only participants who complete the game card with all sponsor stickers and participant contact information will be eligible for the prize drawings. Winners will be drawn at random and must be present at the prize drawing to win. To claim prizes, winners must show identification. Only one prize per participating attendee.

6:05 PM - 7:05 PM Closing Reception

Personal Genetic Service 75+ Reports and at-Home Saliva Kit

Nokia Body Cardio Heart health & body composition wifi scale

CMHC Exhibit Hall Passport to Prizes!

Drawings for all prizes will take place during the Closing Reception on Friday, October 26th. Attendees must be present in the Exhibit Hall to qualify for the prize drawings.